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Pathogenesis
Abstract
Sexual transmission of HIV-1 is often established by one genetic variant, the transmitted/founder (T/F)
virus. T/F HIV-1 may have specific phenotypic properties that are selected for during transmission. To
date, the most consistent phenotypic property associated with T/F viruses is use of the chemokine
receptor CCR5 as a coreceptor for entry. Small molecule CCR5 antagonists, such as Maraviroc (MVC),
inhibit HIV-1 entry by functioning as allosteric inhibitors. These molecules bind within the transmembrane
helices of CCR5, inducing a conformational change that prevents the HIV-CCR5 interaction. As with most
drugs, HIV-1 has developed strategies to overcome this inhibition. Some viruses develop mutations in the
envelope (Env) glycoprotein that enable the use of antagonist-bound CCR5. In Chapter Two, we evaluate
87 CCR5-using viruses to address differences between T/F viruses and viruses isolated from chronically
infected individuals (chronic controls-CC) in their ability to mediate entry via varying amounts of CCR5 in
the presence of MVC. We demonstrate that CC viruses exhibit partial resistance (PR) to MVC more
frequently than T/F viruses, suggesting that T/F and CC HIV-1 differentially utilize CCR5 in a manner that
may be biologically important in the context of transmission. Following the discovery of the chemokine
receptors CXCR4 and CCR5 as cofactors for HIV-1 entry, it was revealed that their cognate chemokine
ligands could inhibit HIV-1 infection in vitro. Multiple cell types have been implicated in secreting
chemokines that function to modulate HIV-1 infection. Recently the platelet-derived chemokine PF4 was
shown to inhibit HIV-1. However, despite plasma and local concentrations of PF4 being within the range
used in these studies, HIV-1 is still able to propagate in vivo. In Chapter Four, we sought to understand the
mechanism of action of PF4 and determine it’s in vivo relevance. I confirmed and extended previous
studies showing that PF4 inhibits infection by HIV-1 and other viruses. However, the inhibitory capacity of
PF4 is limited to a defined concentration range, after which inhibition wanes and viral infection is
ultimately enhanced at higher chemokine concentrations that are commonly found in vivo. Thus, rather
than being a potential anti-viral agent as previously suggested, PF4 may contribute to the hematologic
abnormalities commonly seen in HIV-infected individuals by enhancing virus infection in the bone
marrow.
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ABSTRACT
INSIGHTS INTO THE ROLE OF CHEMOKINES AND CHEMOKINE
RECEPTORS DURING HIV-1 PATHOGENESIS
Zahra F. Parker
Robert W. Doms
Sexual transmission of HIV-1 is often established by one genetic variant,
the transmitted/founder (T/F) virus. T/F HIV-1 may have specific phenotypic
properties that are selected for during transmission. To date, the most consistent
phenotypic property associated with T/F viruses is use of the chemokine receptor
CCR5 as a coreceptor for entry. Small molecule CCR5 antagonists, such as
Maraviroc (MVC), inhibit HIV-1 entry by functioning as allosteric inhibitors. These
molecules bind within the transmembrane helices of CCR5, inducing a
conformational change that prevents the HIV-CCR5 interaction. As with most
drugs, HIV-1 has developed strategies to overcome this inhibition. Some viruses
develop mutations in the envelope (Env) glycoprotein that enable the use of
antagonist-bound CCR5. In Chapter Two, we evaluate 87 CCR5-using viruses
to address differences between T/F viruses and viruses isolated from chronically
infected individuals (chronic controls-CC) in their ability to mediate entry via
varying amounts of CCR5 in the presence of MVC. We demonstrate that CC
viruses exhibit partial resistance (PR) to MVC more frequently than T/F viruses,
suggesting that T/F and CC HIV-1 differentially utilize CCR5 in a manner that
may be biologically important in the context of transmission. Following the
vi

discovery of the chemokine receptors CXCR4 and CCR5 as cofactors for HIV-1
entry, it was revealed that their cognate chemokine ligands could inhibit HIV-1
infection in vitro.

Multiple cell types have been implicated in secreting

chemokines that function to modulate HIV-1 infection. Recently the plateletderived chemokine PF4 was shown to inhibit HIV-1. However, despite plasma
and local concentrations of PF4 being within the range used in these studies,
HIV-1 is still able to propagate in vivo. In Chapter Four, we sought to understand
the mechanism of action of PF4 and determine it’s in vivo relevance. I confirmed
and extended previous studies showing that PF4 inhibits infection by HIV-1 and
other viruses. However, the inhibitory capacity of PF4 is limited to a defined
concentration range, after which inhibition wanes and viral infection is ultimately
enhanced at higher chemokine concentrations that are commonly found in vivo.
Thus, rather than being a potential anti-viral agent as previously suggested, PF4
may contribute to the hematologic abnormalities commonly seen in HIV-infected
individuals

by

enhancing

virus

infection

vii

in

the

bone

marrow.
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CHAPTER 1
Introduction to HIV-1 entry and transmission
HIV-1 ENTRY
Human immunodeficiency virus type I (HIV-1) infection poses a significant
global disease burden, with approximately 34 million people currently infected,
and roughly 2.5 million new cases annually (292). HIV-1 infection leads to
Acquired Immunodeficiency Syndrome (AIDS), which has caused mortality of an
estimated 36 million people since the start of the global pandemic in the mid
1980s, with approximately 1.6 million AIDS-related deaths annually (292). AIDS
is a disease characterized by the gradual decline of circulating CD4+ T cells over
time. Once a threshold of approximately 200 x 109 CD4+ T cells/liter is passed,
the individual is said to be immune compromised and highly susceptible to
opportunistic infections by otherwise non-life-threatening pathogens. Generally,
HIV-1 transmission rates are low, ranging from 0.1% to 10% per coital act (33,
101, 196, 212). However, once an individual becomes infected with HIV-1, a
primary or acute viral infection results within a few weeks, and is characterized
by high viral replication and massive loss of gut associated lymphoid tissue
(GALT) CD4+ T cells. Understanding the early events of HIV-1 infection is
important as they provide insight into the later course of disease. Thus, it is most
appropriate to study the very earliest interactions between the virus and the host
as the starting point of studying HIV-1 pathogenesis. HIV-1 entry into target
1

cells—primarily CD4+ T cells—is mediated by the type I integral membrane viral
glycoprotein Env. The Env precursor (gp160) is proteolytically processed within
the cell, generating the surface unit (gp120) and the transmembrane component
(gp41), which remain associated via non-covalent interactions. Env comprises
gp120 and gp41, and exists as a trimer of heterodimers incorporated into the
viral membrane (296).
HIV-1 entry into cells involves four distinct stages: attachment to the host
cell, binding of gp120 to the primary receptor (CD4), binding of gp120 to the
coreceptor (CCR5 or CXCR4), and gp41-mediated fusion of the viral and host
membranes (Fig 1). The initial, and rate-limiting, step of infection in vitro involves
relatively nonspecific interactions between Env, or other host-derived proteins
within the viral membrane, and cellular attachment factors such as the
negatively-charged glycosaminoglycan (GAG) heparan sulfate proteoglycan
(245). More targeted interactions have also been described between Env and the
C-type lectin dendritic cell–specific intercellular adhesion molecular 3-grabbing
non-integrin (DC-SIGN) (95). DC-SIGN, and other C-type lectins (148, 278, 279),
expressed on dendritic cells can boost HIV-1 infection by binding to highmannose sugars on Env (114) and enhancing infection efficiency in vitro by
transferring bound virions to surrounding CD4+ T cells (a process known as
trans-infection).

Additionally, monomeric HIV-1 Env has been shown to

specifically interact with the gut homing integrin α4β7 (14, 57), which is
approximately three times larger than CD4, making it a prominent attachment
factor for efficient viral capture to increase viral attachment and cell-cell spread.
2

Notably, the discovery of α4β7 as an attachment factor is interesting because the
integrin is upregulated on activated CCR5-expressing CD4+ T cells within the
GALT, a site highly relevant to HIV-1 pathogenesis. Whether α4β7 binds trimeric
Env remains to be investigated. Viral attachment to the cell brings the virus and
cell in close proximity to each other, enhancing the efficiency of infection (194).
While significant, these early, low-affinity interactions are not essential for virus
entry—as is the case for the viral receptor CD4.
The primary receptor for HIV-1 is CD4 (168, 173), a glycoprotein and
member of the immunoglobulin superfamily found on the surface of T helper
cells, monocytes, macrophages, and dendritic cells. HIV-1 Env interacts with
CD4 (145) to initiate a cascade of conformational changes within gp120 required
for successful entry, and with very few exceptions CD4 binding is a prerequisite
for HIV-1 entry. HIV-1 gp120 contains five conserved domains (C1–C5) and five
genetically variable loops (V1–V5). The variable loops are situated at the surface
of gp120 and are involved in immune evasion. V3 is particularly important for
coreceptor binding (109, 266). CD4 binding to gp120 induces major structural
rearrangements in gp120 by inducing the formation of the bridging sheet (formed
by the rearrangement of two pairs of β-sheets from the inner and outer domains
of gp120 into a four-stranded β-sheet structure), rotating each gp120 monomer,
and the extending of the variable loops (V1/V2 and V3). These conformational
changes draw the viral and cell membranes into closer proximity, as well as
create and expose the coreceptor-binding site.

3

Coreceptor engagement follows CD4 binding. In humans, the most
important

coreceptors

are

the

seven-transmembrane

G-protein-coupled

receptors (GPCRs) CCR5 and CXCR4. GPCRs are integral membrane proteins
with an extracellular N-terminal segment, three extracellular loops (ECL) formed
between transmembrane regions, and an intracellular DRY motif that is critical for
G-protein signaling components (Fig 2). CCR5 and CXCR4 are chemokine
receptors, where binding of the cognate chemokine ligands to the chemokines
receptors results in a G-protein-mediated cascade of intracellular signaling
events, which regulate trafficking and the effector response of leukocytes.
Surface expression of various chemokine receptors is specific for certain types of
leukocytes. This expression pattern of chemokine receptors on target cells is the
basis for coreceptor tropism of HIV-1, with some viruses exclusively using CCR5
(R5-tropic), some engaging only CXCR4 (X4-tropic), and others taking
advantage of both (R5X4/dual-tropic) for entry. CCR5 expression is mainly
restricted to memory CD4+ T cells, while CXCR4 expression is more widespread
and predominates on naïve CD4+ T cells (30). Despite this expression pattern,
most infections are initiated by R5-tropic viruses, while disease progression to
AIDS is often associated with the emergence of X4-tropic or dual-tropic variants
(64, 247, 267). Several lines of evidence (3, 23, 76, 84, 266) suggest that both
the tyrosine-sulfated N-terminal segment and the second extracellular loop
(ECL2) are involved in gp120 binding, specifically through interactions with the
bridging sheet and the crown of the V3 loop (which shares striking homology with
the beta2-beta3 loop in chemokines—the natural ligand of chemokine receptors
4

(46)). As such, the amino acids in the gp120 coreceptor-binding site are highly
conserved between HIV-1, HIV-2, and SIV (223, 224), and could serve as
potential targets for the development of broadly-active therapeutic agents.
Binding of gp120 to the coreceptor triggers further conformational changes
in Env that enable gp41-mediated fusion of the viral and cellular membranes.
The current model of gp41-mediated fusion is based on studies of HIV-1 crystal
structures/imaging (52, 290), fusion inhibitors (138, 161, 293), entry kinetic
studies (94, 134, 219), and similarities between gp41 and other wellcharacterized type I membrane fusion proteins including the influenza virus
glycoprotein, hemagglutinin (HA) (52, 290). In this model, following the formation
of Env-receptor-coreceptor complex, the transmembrane gp41 fusion peptide
inserts into the host membrane. The fusion peptide is an N-terminal hydrophobic
portion of gp41 primarily involved in anchoring the viral and cell membranes. The
fusion peptide of each gp41 in the trimer refolds into a thermodynamically stable
structure termed the 6-helix bundle (6HB). The 6HB is formed when an Nterminal helical region (HR1) and a C-terminal helical region (HR2) from each
gp41 subunit come together (52, 290). The energy used to form the 6HB
juxtaposes the viral and host membranes, driving the formation of a fusion pore
(77, 174). Although the mechanisms of fusion for retroviruses have been
extensively studied, the location—plasma membrane or endosome—of the fusion
pore formation remains controversial (280). Reports showing that the majority of
retroviruses do not require low pH to activate the fusion process (62) suggest
that HIV-1 likely fuses with the target cell at the plasma membrane, though it is
5

important to note that pH-independence does not in an of itself imply spatial
information. However, multiple lines of evidence suggest that endocytic entry of
HIV-1 can lead to infection (177), and may be a preferred route of entry into
certain cell types (175). Further studies are needed to elucidate the relevance of
endocytic uptake of HIV-1 in vivo.
INHIBITING HIV-1 ENTRY
Targeting CD4
Each interaction in the multistep HIV-1 entry pathway can be targeted for
drug development. Efforts to block HIV-1 at this stage of infection have led to a
class of interventions termed HIV-1 entry inhibitors. Initial attempts to develop
specific inhibitors of HIV-1 entry focused on blocking viral binding to the cell.
These attempts led to the generation of recombinant soluble CD4 (sCD4)
molecules, which lack the transmembrane and cytoplasmic domains of CD4, but
retain the two outer-most domains (D1 and D2). These constructs maintain the
ability to bind gp120, and thus can act as molecular decoys during infection.
Although sCD4 showed promising in vitro activity against laboratory-adapted
strains of HIV-1 (90, 119, 258, 273), activity in clinical trials did not follow suit (69,
246). Additionally, producing large enough quantities of the protein for clinical
use may be challenging. Furthermore, studies demonstrated that HIV-1 primary
isolates are less sensitive to neutralization by sCD4 than lab-adapted strains (69,
246, 277). Subsequent studies with PRO 542, a tetravalent CD4-Ig fusion protein
comprising D1 and D2 of human CD4 fused to the heavy and light chain constant
regions of human IgG2,κ, yielded more encouraging results (7, 120). Moderate
6

reductions in plasma HIV-1 RNA levels were observed in a phase I trial of PRO
542 in patients with advanced HIV-1 disease. However, disadvantages of this
therapeutic platform are that the drug would have to be delivered intravenously,
would require a cold chain (which is not practical for treating individuals in
resource-limiting settings), and would be expensive to develop.
Conserved structures/domains in gp120, such as the CD4-binding site and
coreceptor-binding domain, serve as attractive targets for antibodies or smallmolecule inhibitors. Unsurprisingly, small molecule inhibitors that block the
gp120-CD4 interaction show greater promise. One such inhibitor (BMS-378806)
(159, 285) exhibits potent antiviral activity in vitro against HIV-1 subtype B
(independent of coreceptor tropism), but is inactive against HIV-2 and SIV (159).
BMS-378806 binds within the CD4 binding pocket of gp120, preventing
engagement with cellular CD4 receptors. The antiviral activity in vivo is
demonstrated by a phase I study with the related compound, BMS-488043,
which resulted in 1-log10-reduction in plasma HIV-1 RNA in study subjects (107).
However, relatively high doses were required (1,800 mg), driving the virus in 17%
of subjects to easily acquire resistance. Moreover, baseline resistance to BMS488043 was detected in another 17% of subjects (306). The compound is no
longer in clinical development.
Small molecules targeting CCR5
Multiple methods have been employed to generate inhibitors targeting the
gp120-CCR5 interaction. Targeting CCR5 has been an attractive therapeutic
angle since the discovery of a naturally occurring mutation in ccr5 (ccr5∆32) that
7

truncates CCR5, preventing cell surface expression of the chemokine receptor.
Individuals homozygous for this mutation are less susceptible to infection by R5tropic HIV-1, although they remain sensitive to infection by X4-tropic viruses
(117, 160, 244), but still these individuals are rarely infected (27, 189, 268). Drug
development efforts to block CCR5 have led to the generation of small molecule
antagonists, monoclonal antibodies (mAbs), and analogues of natural CCR5
ligands. The small molecule CCR5 antagonists have been named with the suffix
“-viroc”, denoting “viral receptor occupancy”. These molecules possess no
agonist properties and do not impact surface expression of CCR5, yet exhibit
potent inhibition of HIV-1 replication in vitro against lab-adapted and primary
isolates across all subtypes of HIV-1. Three of these inhibitors—aplaviroc (APL),
maraviroc (MVC), and vicriviroc (VVC)—have advanced to at least phase II
clinical trials and will be discussed here.
Aplaviroc (formerly, compound 873140) is an allosteric noncompetitive
inhibitor of CCR5, exhibiting potent antiviral activity during short-term
monotherapy studies. Administering 600 mg APL twice daily produced up to a
1.6-log10-reduction in plasma HIV-1 RNA levels during 10 days of treatment
(147). Mechanistic studies showed that nanomolar concentrations of APL block
the activity of the CCR5 ligand, MIP-1α, but not signaling by another CCR5
ligand—RANTES (288). Although initially promising as an antiviral agent, followup studies reported APL-associated hepatotoxicity (drug-induced hepatitis) in 5
subjects during phase IIb and III clinical trials (188). While no fatalities resulted
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from the hepatotoxicity, and pathology resolved with drug discontinuance, APL
development is not being pursued further due to this side effect.
Maraviroc (formerly, UK-427,857) is also a noncompetitive allosteric
inhibitor of CCR5, with potent antiviral activity both in vitro and in vivo. Like APL,
MVC does not induce signaling and calcium mobilization upon binding to CCR5,
nor does it impact CCR5 surface expression. However, unlike APL, MVC is a
functional CCR5 antagonist that blocks binding of, and signaling by, CCR5
ligands including MIP-1α and RANTES at nanomolar concentrations (80). In a
10-day monotherapy phase IIa clinical trial conducted in 63 subjects infected with
R5-tropic HIV-1, 600 mg of MVC daily resulted in ≥1.6 log10-reduction of plasma
HIV-1 (86).
The in vivo efficacy of MVC was confirmed in two double-blind
randomized, placebo-controlled phase III clinical trials—MVC versus Optimized
Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE 1
and 2) (85, 103). MOTIVATE 1 was conducted in the United States and Canada,
and MOTIVATE 2 was conducted in Australia, Europe, and the United States. All
1049 study participants had been taking one or more drugs from at least three
antiretroviral classes and showed evidence of resistance to drugs from these
antiretroviral classes, had plasma HIV-1 RNA levels >5,000 copies/mL, median
CD4 cells count of 169cells/mm3, and were infected exclusively with R5-tropic
virus as assessed by the Trofile assay (164). Participants were randomized to
receive one of two dosing regimens of MVC (300 mg given once or twice daily) or
placebo. At 48 weeks, in both studies, the change in HIV-1 RNA from baseline
9

was greater with MVC than with placebo; -1.66 and -1.82 log10 copies/mL with
the once-daily and twice-daily regimens, respectively, versus -0.80 with placebo
in MOTIVATE 1, and -1.72 and -1.87 log10 copies/mL, respectively, versus -0.76
with placebo in MOTIVATE 2. Additionally, in both studies more than twice as
many MVC recipients had plasma HIV-1 RNA levels below 50 copies/mL
compared to placebo recipients (42-47% in both MVC groups versus 16% in the
placebo group in MOTIVATE 1; 45% versus 18% in MOTIVATE 2). Furthermore,
increases in CD4 cell counts ranged from 110-130 cells/mm3 in the MVC arms as
compared to 50-70 cells/mm3 in the placebo arms.
Repeated Trofile testing showed that when virologic failure occurred, it
was associated with emergence of X4-tropic virus in 57% of subjects (85).
Although all subjects had R5-tropic virus at the failure screening time point, 8%
were found to have dual (X4/R5)-tropic or mixed (X4-tropic and R5-tropic) (D/M)
virus at baseline (day 0). These variants were undetected before MVC treatment
because they were present at levels below the limit of detection of the assay.
Subjects infected with D/M-tropic virus at baseline had a lower rate of virologic
response, shorter time to virologic failure, and smaller CD4 increases as
compared to those exclusively infected with R5-tropic virus. Owing to the results
of the MOTIVATE trials, the makers of MVC received approval by the FDA for
treatment-experienced patients with poor control of multidrug resistant, R5-tropic
HIV-1.
While the approval of MVC targets the treatment of patients with R5-tropic
virus, its potential in patients with D/M-tropic virus has also been evaluated (230).
10

A total of 186 study participants infected with D/M-tropic virus, with median CD4
cell counts of 42 cells/mm3 and HIV-1 viral load of >5000 copies/mL within each
cohort (300 mg MVC once-daily, twice-daily, or placebo), were enrolled in a
randomized double-blind, placebo-controlled phase IIb clinical trial A4001029.
This study found no significant virologic benefit of MVC as compared to placebo
over 24 weeks. These results and those of the MOTIVATE trials suggest that
although the presence or outgrowth of X4-tropic virus dampened the response to
MVC, it was not associated with rapid CD4 decline or disease progression.
Vicriviroc, (formerly, SCH417690 or SCH-D) is a third class of allosteric
noncompetitive CCR5 inhibitor. VVC is an orally bioavailable small molecule
CCR5 antagonist that, like MVC, blocks signaling by the C-C chemokines at
nanomolar concentrations (265). Early in vivo studies demonstrated that VVC
produced seizures in animals at high doses, but no VVC-associated adverse
effects in the CNS have been reported in human clinical trials. A 14-day
monotherapy trial demonstrated a reduction of plasma HIV-1 RNA by
approximately 1.0-1.5 log10 copies/mL (248). However, a phase IIb study of VVC
(plus dual nucleoside reverse-transcriptase inhibitors—NRTIs) in treatment-naïve
HIV-1-infected subjects was halted due to increased rates of virologic failure in
the VVC arms compared to the control dual NRTI arm (149). Despite these
setbacks, a placebo-controlled phase IIb study conducted in antiretroviralexperienced participants demonstrated potent suppression of HIV-1 by VVC
(administered at 5, 10 or 15 mg daily) in combination with a protease inhibitor
(297). Mean changes in plasma HIV-1 RNA levels at 24 weeks ranged from 1.511

1.9 log10 copies/mL in the VVC-treated participants as compared to 0.29
log10 copies/mL in the placebo group. The same trend was observed 48 weeks
post treatment. However, development of VVC was not further pursued due to
lack of convincing efficacy gains when it was added to background therapy
comprising two antiretroviral drugs in two randomized phase III clinical trials (48).
Targeting CXCR4
As with CCR5, the development of small molecule inhibitors of CXCR4
has been an attractive therapeutic option (262). Initial animal toxicity studies with
two small molecule inhibitors (AMD3100 and AMD11070) (78) provided enough
evidence of safety to proceed with human studies (110). Preliminary human
studies with AMD3100 showed selective blockade of CXCR4 and inhibition of
X4-tropic HIV-1 and HIV-2, but development of this compound as an anti-HIV-1
drug was discontinued because it lacked bioavailability and caused substantial
peripheral leukocytosis—mobilization/release of progenitor hematopoietic stem
cells from the bone marrow into the blood (91, 110). This side effect turned out to
be a benefit, though not for HIV-1, as AMD3100 (now known as plerixafor) has
since been approved for use during autologous transplantation in patients with
non-Hodgkin’s lymphoma and multiple myeloma (43, 75). Phase I and II studies
with another CXCR4 inhibitor AMD11070 showed a reduction in the X4-tropic
HIV-1 population in participants infected with D/M virus (180). However, further
development of this drug has been halted due to abnormal liver histology in longterm animal studies. The long-term safety of targeting CXCR4 remains in
question.
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Targeting fusion
Membrane fusion mediated by HIV-1 gp41 is yet another viable drug
target in the HIV-1 entry pathway. Because the 6HB structure is critical for
membrane fusion, peptide inhibitors mimicking the HR1 or HR2 region of the
gp41 subunit have been designed to prevent membrane fusion (122). One such
peptide, enfuvirtide (T20), is the only FDA-approved HIV-1 fusion inhibitor (147,
151). T20 is a 36-mer synthetic peptide whose sequence matches that of the
HR2 region of gp41. Interaction of T20 with HR1 prevents the association of HR1
with HR2, thus inhibiting fusion and blocking virus entry (294). The drug has
minimal toxicity, however because it is a peptide, it must be administered by
subcutaneous injection. T20 co-administered with other drugs (darunavir,
tirapanavir, and maraviroc) in clinical trials lead to significant improvements in
response rates to those compounds (58, 112). Unfortunately, as with most entry
inhibitors, viral resistance to T20 emerges rapidly; predominantly in regimens
where viral inhibition is incomplete or due to naturally occurring polymorphisms in
the gp41 region of genetically diverse forms of HIV-1 (47, 208). This underscores
the need for combination therapy in the management of HIV-1 infection (124,
282).
THE VIRAL BOTTLENECK DURING HIV-1 SEXUAL TRANSMISSION
The majority of new HIV-1 infections occur in the developing world, with
women being disproportionally affected compared to men. Of these new
infections, approximately 80% result from heterosexual intercourse (65, 228,
13

298). Sexual transmission of HIV-1 is an inefficient process, with the incidence of
transmission between discordant couples being estimated to be between 0.1%10% transmission rate per coital act (33, 101, 196, 212). Sexual transmission of
HIV-1 is characterized by a genetic bottleneck in which one or few viral variants
from the diverse viral swarm in the donor cross the mucosal epithelium in the
recipient and encounter susceptible target cells to seed the infection. This theory
of the genetic bottleneck was initially described over 20 years ago, when
researchers studying donor-recipient pairs discovered that viral sequences
isolated from recipients were usually homogenous and macrophage-tropic, while
viral populations of the donors showed heterogeneity both in sequence and cell
tropism (299, 300, 304, 307). Other studies suggested that multiple viral variants
may initially cross the physical mucosal barrier, however most are extinguished
due to intrinsic differences in reproductive rates (131, 152, 154). As a result,
successful transmission generally results from the expansion and propagation of
a single genetic variant, termed the transmitted/founder (T/F) virus (Fig 3) (131).
T/F viruses may have specific properties that are selected for during
transmission, and identifying such traits may inform and facilitate the
development of pre- and post-exposure therapies targeting these early viruses.
KNOWN PROPERTIES OF TRANSMITTED HIV-1
The first report of genotypic differences between viruses isolated from
donor-recipient pairs came from studies of vertical transmission of three motherinfant pairs (300). Infant viral sequences of the V3-V5 region of Env were less
diverse than those from their respective mother. Additionally, a potential N-linked
14

glycosylation site (PNLG) within V3 was conserved in each mother’s sequences,
but lost in her corresponding infant’s viral sequences. Furthermore, fewer PNLGs
have been reported in vertically transmitted subtype A and C Envs isolated from
mother-infant pairs (229, 301, 303). These data suggest that viruses with fully
glycosylated Envs are perhaps selected against as they traverse the placenta
into the infant host, or may acquire a fitness cost that hampers their replication in
the new host (303).
While these early studies in mother-to-child transmission (MTCT) pairs
were invaluable as MTCT accounted for approximately 25% of global
transmission during that time (1991) (35), by 1994 MTCT rates had began to
dramatically drop (to as low as 4%) owing to the development of highly active
therapy preventing vertical transmission (63, 207). This highlighted the
importance of studying transmission in pairs that characterized the majority of the
pandemic—sexually transmitted pairs. As observed in MTCT pairs, analysis of
Envs from acutely infected individuals with subtype C infection also revealed
shorter variable loops with fewer PNLGs compared to those from their
transmitting partners (73). Other studies reported shorter V1 and V2 regions and
fewer PNLGs in acutely infected individuals with subtype A and B virus (56, 235).
Moreover, an assessment of thousands of Env sequences to discern patterns in
amino acid signatures that are significantly associated either with transmission or
with the chronic phase of the infection revealed two statistically associated
signatures of acute viruses; the first was located at position 12 in the signal
peptide, and the second was a loss of a PNLG in the cytoplasmic tail of gp41
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(96). These genotypic signatures are likely not randomly transmitted as work by
multiple groups has shown that T/F viruses arise from a minor population of the
donor’s plasma virus (32, 93, 300). Furthermore, studies have shown that these
transmitted minor variants are genetically similar to sequences isolated from
earlier time points in the donor, not those circulating at the time of transmission
(218), suggesting that the donor’s plasma quasispecies at the time of
transmission may not accurately predict the T/F virus. These data also support
the theory that certain genotypic (or phenotypic) properties are particularly
favored during transmission, and are selected even when they account for the
minority of sequences present in the donor.
Given the genotypic evidence of the transmission bottleneck, many groups
have sought to identify the viral traits/phenotypes that account for transmission
fitness by comparing HIV-1 envelope glycoprotein (env) sequences from
chronically infected individuals with those isolated from their newly-infected
partners. Multiples studies reported that viruses that are transmitted between
individuals preferentially use CCR5 to mediate entry into target cells (51, 121,
131, 199, 200, 239, 295). This provides some insight into why, as mentioned
above, individuals who are homozygous null for ccr5 rarely become infected,
even though they remain susceptible to infection by X4-tropic viruses (27, 189,
268). Additional studies showed that one or few viruses with compact, glycanrestricted Envs that were sensitive to donor neutralizing antibodies, typically
established new infections (56, 68, 73, 96, 157, 162). While other groups have
not been able to confirm the neutralization sensitivity of T/F Envs (31, 92, 229),
16

these initial studies served to stimulate research interest in this area. Recent
work from Beatrice Hahn and George Shaw has attempted to more precisely
identify targetable traits of transmitted viruses using single-genome amplification
with replication competent subtype B and C viruses (199). They found that T/F
viruses were marginally more infectious and contained approximately twice more
Env per virion compared to chronic viruses. T/F viruses were more readily
transferred to CD4+T cells by dendritic cells, but replicated with similar kinetics in
primary cells as chronic viruses. Lastly, T/F were more resistant to IFN-α
treatment compared to chronic viruses.
While the field has made great progress in elucidating properties that are
associated with transmitted HIV-1, so far the only consistent phenotype
associated with transmitted viruses is the use of CCR5. Approximately one-half
of transmissions are thought to occur when the donor is still in the acute stage of
infection (209, 289), therefore this property may have easily been missed had the
studies discussed above not assessed differences between T/F viruses and
viruses isolated from chronically-infected individuals, where X4-tropism is more
prevalent (28, 202, 222, 247, 261). This underscores the importance of
comparing T/F viruses to chronic viruses to increase the likelihood of detecting
subtle differences that significantly impact transmission that may otherwise be
overlooked. The genotypic and phenotypic properties outlined here likely act in
concert to evade host immune pressure and foster viral diversification, and may
serve as attractive therapeutic targets for the development of AIDS interventions.
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PROJECT GOAL I: IDENTIFYING
TRANSMITTED VIRUSES

TARGETABLE

PROPERTIES

OF

T/F viruses may have specific properties that are selected for during
transmission, and identifying such traits may inform and facilitate the
development of pre- and post-exposure therapies targeting these early viruses.
To date, the most consistent property associated with transmitted viruses is the
use of the CCR5 coreceptor. CCR5 is a GPCR that functions as a chemokine
receptor to regulate trafficking and the effector response of leukocytes. Ligand
(MIP1-α, MIP1-β, and RANTES)-binding induces a conformational change of the
protein and activates trimeric G-proteins, which leads to subsequent signaling
events that mediate CCR5 effector function. Thus, like other GPCRs, CCR5 is
conformationally plastic. We, and others, have used conformation-dependent
monoclonal antibodies to confirm antigenically distinct forms of CCR5 on primary
cells and cell lines (25, 153). The impact of this conformational heterogeneity on
infection varies by virus strain. We know that viruses differ in their ability to
interact with CCR5, with some viruses being heavily reliant on the amino
terminus (NT) and others on the second extracellular loop (ECL2) for entry (3,
272). Additionally, some viruses are naturally capable of utilizing structurally
altered antagonist-bound CCR5 for entry (108, 271).
Although we know that a spectrum of CCR5 engagement by various HIV-1
exists, the implications of these interactions are unknown. We were interested in
understanding how various viruses interact with CCR5—particularly, different
conformations of CCR5. To this end, I evaluated a panel of 87 R5-tropic viruses
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(from MVC treatment-naïve patients) to address differences between T/F and
chronic control (CC) HIV-1 in their ability to mediate entry via varying amounts of
CCR5 in the presence of MVC. Our lab had previously reported no statistical
difference in MVC sensitivity between subtypes B and C T/F and CC viruses on a
microglial cell line—NP2/CD4/CCR5 (200, 295).
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Figure 1: HIV-1 entry process. HIV-1 entry can be divided into three key steps, all mediated by the viral envelop glycoprotein (Env)
gp120. First, nonspecific, low-affinity interactions bring the virion into close proximity to the cell surface, allowing gp120 to bind to the
receptor CD4. Second, CD4 binding induces a conformational change in Env exposing the coreceptor binding site and facilitating
coreceptor (typically, CCR5 or CXCR4) engagement. Coreceptor binding induces another structural change in Env, triggering the
formation of the fusion pore and membrane fusion of the viral and host membranes. (Image from Wilen et al. Adv Exp Med Biol. 2012;
726: 223-42)
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Figure 2: Schematic of CCR5 coreceptor. CCR5 is a seven-transmembrane G-protein-coupled receptor (GPCR) that functions as a

chemokine receptor, and serves as a coreceptor for HIV-1 infection. HIV-1 Env binds the 352 amino acid protein at the amino terminus (Nterminus) and/or the second extracellular loop (ECL2) at the pink and purple colored residues, respectively. Sites of posttranslational
modifications are also shown and contribute to changes in CCR5 3D structure. Conformational plasticity is a key feature of GPCRs such
as CCR5. (Image adapted from Lopalco et al. J Transl Med 2010 9 (Suppl 1):S4)
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Adapted from B Keele

Figure 3: HIV-1 genetic bottleneck. Sexual transmission of HIV-1 is characterized by a genetic bottleneck in which a diverse viral swarm
in the donor, represented by the differentially-colored virions on the left, must initially cross the mucosal epithelium in a new host and
encounter target cells to infect. Multiple variants may cross this physical barrier, however the majority will die out or be outcompeted. As a
result, approximately 80% of the time, successful transmission is carried out by a single genetic variant, termed the transmitted/founder
(T/F) virus. (Image adapted from Brandon Keele)
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ABSTRACT
Infection by HIV-1 most often results from the successful transmission and
propagation of a single virus variant, termed the transmitted/founder (T/F) virus.
Here, we compared the attachment and entry properties of envelope (Env)
glycoproteins from T/F and Chronic Control (CC) viruses. Using a panel of 40 T/F
and 47 CC Envs, all derived by single genome amplification, we found that 52%
of clade B and C CC Envs exhibited partial resistance to the CCR5 antagonist
maraviroc (MVC) on cells expressing high levels of CCR5, while only 15% of T/F
Envs exhibited this same property. Moreover, subtle differences in the magnitude
with which MVC inhibited infection on cells expressing low levels of CCR5,
including primary CD4+ T cells, was highly predictive of MVC-resistance when
CCR5 expression levels were high. These results are consistent with previous
observations showing a greater sensitivity of T/F Envs to MVC inhibition on cells
expressing very high levels of CCR5 and indicate that CC Envs are often capable
of recognizing MVC-bound CCR5, albeit inefficiently on cells expressing
physiologic levels of CCR5. When CCR5 expression levels are high, this
phenotype becomes readily detectable. The utilization of drug-bound CCR5
conformations by many CC Envs was seen with other CCR5 antagonists, with
replication competent viruses, and did not obviously correlate with other
phenotypic traits. The striking ability of clade B and C CC Envs to use MVCbound CCR5 relative to T/F Envs argues that the more promiscuous use of
CCR5 by these Env proteins is selected against at the level of virus transmission
and is selected for during chronic infection.
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INTRODUCTION
Physical and innate immune barriers serve to make mucosal transmission
of HIV-1 a relatively inefficient process.

As a result, establishment of virus

infection in a naïve host most often results from the transmission and subsequent
propagation of a single virus strain, termed a transmitted/founder (T/F) virus (19,
73, 131, 158, 198, 210, 299, 300, 304, 307). Virologic traits that might enable a
virus to overcome one or more of these barriers could be selected for during
transmission, and identification of such traits should lead to a greater
understanding of the earliest events in HIV-1 infection and could suggest new
prevention strategies.
Single genome amplification has enabled the inference of a large number
of T/F envs from multiple virus clades (1, 105, 131, 190, 238, 239). This has
made it possible to seek genotypic and phenotypic differences between T/F Env
proteins and those derived from chronically infected individuals (CC Envs).
Several phenotypic characteristics are clearly associated with transmission: T/F
Envs virtually always use CCR5 rather than CXCR4 or other non-canonical
coreceptors (24, 51, 121, 131) and generally infect T cells but not macrophages
(131, 190, 239, 295) as a result of requiring relatively high levels of CD4 to
mediate virus entry (98, 171, 182, 203, 204, 242). Other phenotypic and
genotypic traits that have been linked to transmission are less well defined: Envs
isolated from acute infection have sometimes been reported to be more
neutralization sensitive (295) have on average fewer putative N-linked
glycosylation sites (73, 96), and have shorter variable loops (56, 73, 234, 235)
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compared to Envs isolated from chronically infected individuals.
Recently, Swanstrom and colleagues reported an additional phenotypic
difference between clade C T/F and chronic Env proteins (127). They found that
CC Envs were more likely than T/F Envs to exhibit partial resistance to the CCR5
antagonist maraviroc (MVC) on 293T cells expressing high levels of CCR5, but
not on 293T cells expressing lower levels of CCR5. This finding suggests that CC
Envs are often capable of infecting cells by using the MVC-bound conformation
of CCR5 or that they are able to utilize a form of CCR5 that is unable to bind
MVC. However, work by us and others has not revealed differences in MVC
sensitivity between T/F and CC Envs on an NP2 cell line (200, 219, 272, 295).
To reconcile these findings, we examined a previously described panel of
clade B and clade C Env proteins from T/F and chronic viruses (200, 295) for
their ability to infect cell lines and primary human CD4 + T cells in the presence
of saturating concentrations of MVC. On 293T cells expressing high levels of
CCR5, we confirmed that clade C CC Envs were much more likely than T/F Envs
to mediate infection in the presence of MVC as shown by Swanstrom and
colleagues with a different panel of clade C Env proteins (127). We found this
property to be shared by clade B Envs and extended these observations further
to include cell lines expressing 5- to 10-fold lower levels of CCR5 and on primary
human CD4 + T cells. Subtle differences in the efficiency with which MVC
inhibited infection of 87 different T/F and chronic viruses on cells expressing low
levels of CCR5 was highly predictive of more overt MVC-resistance when CCR5
expression levels were high.

This property was also seen with other CCR5
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antagonists, with replication competent infectious molecular clones (IMCs), and
did not correlate with other phenotypic properties. Since the efficiency of virus
entry in the presence of MVC increased with CCR5 expression levels, we
conclude that many CC Envs can utilize at least some of the drug-bound
conformations of CCR5, albeit inefficiently. Nonetheless, the differential ability of
clade B and C chronic and T/F Envs to use MVC-bound CCR5 argues that the
more promiscuous use of CCR5 conformations by many chronic viral Env
proteins is selected against at the level of virus transmission by a mechanism(s)
that has not yet been elucidated by in vitro assays, but is selected for during
chronic infection. Differences in the populations of CD4+CCR5+ cells that are
targeted by HIV in acute versus chronic infection may reveal differences in how
T/F and CC Envs mediate virus infection and could suggest new prevention
strategies.
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MATERIALS AND METHODS
Description of Envs and infectious molecular clones (IMCs). The
derivations of all the Env clones and IMCs used in this study have been
described previously (131, 200, 239, 295). Briefly, the sequences of all Envs and
IMCs were inferred from single genome sequencing of acute or chronically
infected donors. The Envs or IMCs were then amplified from the first-round PCR
product or gene synthesized and then sub-cloned into pCDNA3.1+ directional
TOPO or pCRXL TOPO vector (Invitrogen). Clade B CC Envs were randomly
selected amongst sequences from the chronic swarm that were predicted to be
functional, while clade C CC Envs were generated by determining the mostrecent common ancestor of discrete clonally-expanded populations, evident as
minor populations in phylogenetic trees of chronic sequences (200). A summary
of the geographic origin and infection status for Envs and IMCs is shown in Table
S1.
Cell

culture.

293T17,

293T-derived

Affinofile,

NP2/CD4/CCR5,

NP2/CD4/CXCR4, and U87/CD4 cell lines were maintained in Dulbecco’s
modified Eagle medium (DMEM) with 10% (vol/vol) fetal bovine serum (FBS)
(Sigma-Aldrich) and 1% penicillin/streptomycin. Affinofile cells were maintained in
DMEM supplemented with 10% FBS, 1% penicillin/streptomycin per ml, 50 μg/ml
blasticidin per ml, and 200 μg/ml G418 per ml.
Pseudovirus production and normalization. HIV-1 Env pseudoviruses
were produced by calcium phosphate co-transfection of 6 µg of pcDNA3.1+
containing the desired env clone with 10 µg of HIV-1 core (pNL43-ΔEnv-vpr+-luc+
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or pNL43-ΔEnv-vpr+-eGFP) into 293T17 cells. At 72 h post transfection, the
pseudovirus-containing supernatant was harvested and filtered through a 0.45µm filter, aliquoted, and stored at -80°C. For primary CD4+ T cell infections,
pseudovirus was concentrated approximately 100-fold by ultracentrifugation at
113,000 x g for 2 h at 4°C through a 20% sucrose cushion. Pelleted pseudovirus
was then resuspended in phosphate-buffered saline (PBS). All luciferaseencoding pseudoviral stocks were serially diluted on NP2/CD4/CCR5 cells to
define the linear range of the assay. Relative light units (RLUs) of all viruses
used were well within the 5-log linear range of the assay.
Virus inhibition assays. The HEK293T-based CD4/CCR5 dual-inducible
cell line (Affinofile) was employed to assess sensitivity of pseudovirions and
replication competent viruses to CCR5 antagonists at different levels of CCR5
surface expressions. CD4 expression was induced with minocycline and CCR5
expression

was

induced

with

ponasterone

A

(pon

A)

as

described

previously(126). Briefly, 650 cells were plated in each well of a 96-well plate and
then 48 h later they were induced with a final concentration of 10 ng/ml
minocycline to maximally express CD4 and either 2 µM or 0.031 µM pon A to
express high and low CCR5, respectively. 18 h post-induction, CD4 and CCR5
expression levels were determined by quantitative flow cytometry (BD
QuantiBrite) as described below. Induced Affinofile cells, NP2/CD4/CCR5 or
U87/CD4 cells transiently transfected with pcDNA3.1+ encoding CCR5 using
Lipofectamine 2000 (Invitrogen) were used for CCR5 antagonist inhibition
studies. Cells were preincubated for 30min at 37°C with either 2µM of drug,
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previously shown to be saturating (57), or three-fold serial dilutions from 6µM to
0.1µM of the CCR5 antagonists maraviroc (MVC), aplaviroc (APL), CMPD-167,
TAK-779, vicriviroc (VVC), or media alone prior to infection with the indicated
luciferase reporter pseudovirus. After addition of pseudovirus, plates were
spinoculated at 450 x g for 2 h at 4°C and then incubated at 37°C. We also
performed experiments without spinoculation and obtained similar results:
spinoculation increased infection by approximately 2-fold, but did not impact the
sensitivity of viruses to maraviroc. Cells were lysed with Brite-Glo (Promega) at
72 h post-infection and relative light units (RLUs) assessed on a Luminoskan
Ascent luminometer. All inhibition assays were done in triplicate in each of at
least two independent experiments using a MVC-sensitive and MVC-partially
resistant R5-tropic Env as controls.
Primary human CD4+ T cell infections. Primary human CD4+ T cells,
purified by negative selection, were obtained from the Human Immunology Core
of the University of Pennsylvania’s Center for AIDS Research (CFAR). Cells
were infected as described previously (295). Briefly, 1.5 x 106 cells per condition
were stimulated with plate-bound anti-CD3 (clone OKT3; eBiosciences) and antiCD28 (clone 28.2; BD Biosciences) and 20 U/ml recombinant interleukin-2 (IL-2;
Aldesleukin) in Rosewell Park Memorial Institude (RPMI) medium containing
10% FBS. Three days post-stimulation cells were transferred to 96-well V-bottom
plates and incubated for 30 min with 6µM MVC or a no drug control.
Approximately 5µg p24 of concentrated HIV-green fluorescent protein (GFP)
pseudovirus was used to infect cells in triplicate in a total volume of 50µl at a cell
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concentration of 1 x 107 cells/ml. Plates were then spinoculated at 1,200 x g for 2
h at 4°C. Cells were resuspended at 1 x 106 cells/ml. Three days post-infection,
cells were stained with live/dead aqua (1µl) (Invitrogen), anti-CD4 Alexa Fluor
700 (2µl) (Invitrogen), and anti-CD3 Qdot 655 (0.5µl) (Invitrogen) and examined
by flow cytometry and the fraction of cells that were GFP-positive determined.
HIV-infected cells were defined as live/dead CD3+CD4-GFP+ as cell surface
CD4 is down-regulated upon infection.
Flow cytometry. Cell staining was perferomed at room temperature in
50µl FACS wash buffer (PBS, 2.5% FBS, 2 mM EDTA). For CD4

+

T cells, cells

were first washed in PBS, then live/ dead aqua (Invitrogen) was added and
incubated for 10 min. Next, anti-CCR7 IgM (1µl) in FACS buffer was added and
incubated for 30 min. Cells were then washed in FACS buffer before staining with
anti-CD4–Qdot 655 (0.5µl) (Invitrogen), anti-CD45RO–phycoerythrin (PE)-Texas
Red (3µl) (Beckman Coulter), and anti-CCR5 (2D7)–PE (5µl) (BD Biosciences)
for 30 min. Cells were then washed in FACS buffer and resuspended in 1%
paraformaldehyde (PFA). Samples were run on an LSRII (BD) instrument and
analyzed with FlowJo 10.0 (Treestar). Cells were gated as follows: singlets (FSCA by FSC-H), then live cells (SSC-A by live/dead), then lymphocytes (SSC-A by
FSC-A), then CCR5+ cells (SSC-A by 2D7-PE).
Quantitative FACS. Quantitative FACS was performed to convert mean
fluorescence intensity (MFI) into antibody-binding sites (ABS) by using a
standardized microbeads kit (BD Biosciences) according to the manufacturer’s
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instructions. The MFI of the isotype control for each experiment was converted to
ABS and subtracted from the ABS value obtained with the experimental sample.
Statistical and correlation analyses. Infection values obtained with T/F
and chronic Env pseudovirions were compared using Mann-Whitney tests,
Fisher’s exact, or t-tests, and correlations were assessed using Spearman tests.
P-values of less than 0.05 were considered significant. Data were analyzed with
Prism 5.0 software.
Ethics statement. All human cells used in this study were from normal
healthy donors who provided written informed consent after approval by the
University of Pennsylvania’s Institutional Review Board.
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RESULTS
Partial resistance to MVC on Affinofile cells with high CCR5 surface
expression. Swanstrom and colleagues observed that chronic clade C Envs
mediate low levels of infection on Affinofile cells expressing high levels of CCR5
in the presence of MVC more frequently than T/F Envs. To assess if an
independent panel of 87 clade B and C Envs (200, 295) would recapitulate this
finding, we also utilized the 293T-derived Affinofile cell system. Among these
pseudoviruses were 24 clade B and 16 clade C T/F Envs, as well as 28 clade B
and 19 clade C CC Envs, all derived by single-genome amplification and
described in earlier reports (131, 200, 295). The Affinofile cell line makes it
possible to independently modulate surface expression of CD4 and CCR5 by
applying different concentrations of the transcriptional activators minocycline and
pon A, respectively (126).We examined the sensitivity of HIV-1 Env
pseudoviruses to MVC on Affinofile cells expressing relatively low (low CCR5
Affinofile cells) or high levels of CCR5 (high CCR5 Affinofile cells), while
maximally inducing CD4 levels. PonA treatment increased the overall expression
of CCR5 on Affinofile cells from 2,723 (uninduced) to 23,470 (high induction)
antibody binding sites (ABS) per cell (Fig. 1A). To confirm that 6µM MVC was
saturating at the highest level of CCR5 expression, we assessed the difference in
residual infection between the two highest concentrations of MVC employed and
found that there was no increase in inhibition of infection from 2µM to 6µM MVC,
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indicating that 2µM was saturating and that further increases in drug did not have
any additional inhibitory effect (P = 0.70 by paired t-test) (Fig. 1B).
Affinofile cells expressing low or high levels of CCR5 were infected by
each of the 87 pseudoviruses in the presence or absence of increasing
concentrations (to a maximum of 6µM) of MVC, after which we calculated the
maximal percent inhibition (MPI). We imposed an arbitrary MPI cutoff of 95%,
where MPI values >95% were considered MVC sensitive, while samples with
MPIs less than or equal to 95% were assumed to be partially resistant to MVC.
We found that infection by all 87 pseudoviruses was inhibited by >95% at
saturating concentrations of MVC on low CCR5 Affinofile and NP2/CD4/CCR5
cells, consistent with our previous results (200, 295). On high CCR5 Affinofile
cells, 57 of 87 (66%) of the pseudoviruses were inhibited by MVC by >95%
(representative pseudovirus is shown in Fig. 1C, top panel), while 30 of 87 (34%)
of the pseudoviruses exhibited partial resistance defined by a MPI ≤ 95% in the
presence of 6µM MVC, with some pseudoviruses exhibiting considerable MVC
resistance (MPI values as low as 60%) (Fig. 1C, middle panel). JRFL, which is
MVC sensitive, was included as a control in all experiments (Fig. 1C, bottom
panel). When CCR5 levels were high, the amount of MVC needed to achieve
maximal inhibition increased for all viruses as expected. These results confirmed
a central finding of Swanstrom and colleagues (127), in that a considerable
number of viruses do indeed exhibit a reduced MPI when MVC is used to inhibit
infection on high CCR5 Affinofile cells.
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Partial MVC resistance is enriched in chronic HIV-1, but is not clade
or antagonist specific. There was a striking difference in the frequency with
which T/F and CC Envs exhibited partial MVC resistance (15% [6 of 40] versus
52% [24 of 47]; P < 0.0001 by Fisher’s exact test) (Fig. 2A). This partial
resistance was not clade-specific as 50% (14 of 28) of clade B and 53% (10 of
19) of clade C CC Envs exhibited partial resistance to MVC, whereas only 17%
(4 of 24) of clade B and 13% (2 of 16) of clade C T/F Envs exhibited this property
under conditions of high CCR5 expression (clade B P =0.02, clade C P = 0.02
by Fisher’s exact test) (Fig. 2B). Not only was the distribution of MVC-sensitive
and resistant Envs similar for clade B and C pseudoviruses, but these
distributions were similar to those reported by Swanstrom and colleagues with
their panel of clade C Envs (127). Thus, partial resistance to MVC on cells
expressing high levels of CCR5 is reproducible, and is not clade specific.
To assess if MVC-resistance predicted resistance to other CCR5
antagonists, we evaluated the sensitivity of four partially MVC-resistant
pseudoviruses to four additional small molecule CCR5 inhibitors: aplaviroc,
CMPD-167, TAK-779, and VVC. Similar to the results with MVC, all four
pseudoviruses tested were inhibited by >95% by all CCR5 antagonists on
Affinofile cells expressing low levels of the coreceptor. However, at high CCR5
surface expression, all four pseudoviruses were partially resistant to the other
CCR5 antagonists, similar to the results obtained with MVC (representative
results shown in Figure 2C). Furthermore, the residual infection seen at high
levels of CCR5 on Affinofile cells in the presence of CCR5 antagonists was not
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due to the use of low endogenous levels of CXCR4 present on 293T cells, as the
addition of the CXCR4 inhibitor AMD3100 did not affect the MPI of partially
resistant pseudoviruses (data not shown). Finally, we tested four IMCs whose
Env proteins had been tested as part of the pseudovirus panel, including two T/F
IMCs that were sensitive to MVC on high CCR5 Affinofile cells and two chronic
IMCs that exhibited partial MVC resistance. The results with the replication
competent

viruses

mirrored

the

results

obtained

with

the

respective

pseudoviruses (data not shown), indicating that the partial resistance phenotype
observed under conditions of high CCR5 is not an artifact of the pseudotyping
system. Taken together, these results suggest that clade B and C CC Envs
exhibit partial resistance to CCR5 antagonists at high levels of CCR5 much more
frequently than T/F Envs.
MVC sensitivity on cells expressing low CCR5 levels predicts MVC
resistance on cells expressing high levels of CCR5. We previously reported
that T/F and chronic Env pseudovirus infection of NP2/CD4/CCR5 cells
expressing CD4 and CCR5 were equally sensitive to MVC, exhibiting similar IC50
values. In addition, all T/F and CC Envs were inhibited by saturating
concentrations of MVC by >95% (200, 295). However, dose-response curves
with different slopes can appear similar on traditional semi-log plots, masking
differences in maximal inhibition (243, 252). Therefore, we performed new
infection assays using the entire panel of viruses on NP2/CD4/CCR5 cells, which
stably express intermediate levels of CCR5 (Fig. 1A), and compared the results
to those obtained on low CCR5 and high CCR5 Affinofile cells by plotting the
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residual infection for each virus on a log-scale (Fig. 3). While MVC inhibited all
pseudoviruses by >95% on both low CCR5 Affinofile and NP2/CD4/CCR5 cells,
there was considerable variability in residual infection values for different T/F and
chronic Env pseudotypes. On NP2/CD4/CCR5 cells there was a significant
difference in median residual infection between T/F and CC Envs (T/F
median=0.06%, chronic median=0.15%; P = 0.01 by Mann-Whitney test). The
magnitude of this difference was more pronounced on high CCR5 Affinofile cells
(T/F median=0.54%, chronic median=4.8%; P = 0.0003 by Mann-Whitney test)
but was not apparent on low CCR5 Affinofile cells (T/F median=0.18%, chronic
median=0.14%; P = 0.94 by Mann-Whitney test). When we re-examined the
NP2/CD4/CCR5 infection data from our previous studies (200, 295), the same
correlations were observed.
Are the low and variable levels of infection on low CCR5 Affinofile and
NP2/CD4/CCR5 cells in the presence of MVC predictive of more efficient
infection in the presence of MVC when CCR5 levels are high? To determine this,
we plotted residual infection on low CCR5 Affinofile (Fig. 4A) or NP2/CD4/CCR5
cells (Fig. 4B) in the presence of saturating MVC against that of each virus on
high CCR5 Affinofile cells in the presence of saturating MVC. We found a
moderate correlation between these values when comparing low CCR5 Affinofile
and high CCR5 Affinofile cells (Spearman correlation coefficient= 0.22; P = 0.04)
(Fig. 4A) and a more significant correlation when comparing NP2/CD4/CCR5 to
high CCR5 Affinofile cells (Spearman correlation coefficient= 0.65; P < 0.0001)
(Fig. 4B). These results argue that an appreciable number of CC Envs can
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utilize MVC-bound CCR5 but that this ability is less obvious on cells expressing
low to moderate levels of CCR5, unless results are plotted on a log scale. When
this is done, small differences in residual virus infection are not only evident, but
highly predictive of substantive infection when CCR5 expression levels are high.
To further confirm this finding, we examined a subset (4 T/F and 8 CC Envs) of
our pseudoviruses on U87/CD4 cells in which CCR5 was transiently expressed,
resulting in high levels of CCR5 (Fig. 1A). These experiments recapitulated our
findings on high CCR5 Affinofile cells: viruses that exhibited MPIs of <95% on
high CCR5 Affinofile cells likewise exhibited reduced MPIs on transiently
transfected U87/CD4 cells, while viruses that remained highly sensitive to MVC
under these conditions were likewise efficiently inhibited on CCR5-expressing
U87/CD4 cells (data not shown).
Utilization of CCR5 in the presence of MVC is evident on primary
human CD4+ T cells. To assess whether this phenotype is recapitulated under
more physiologically relevant conditions, we infected primary human CD4+ T
cells with GFP-expressing Env pseudoviruses in the presence or absence of
saturating concentrations of MVC. To maximize the sensitivity of this primary cell
assay, we selected three T/F pseudoviruses that were efficiently inhibited by
MVC on high CCR5 Affinofile cells and three chronic pseudoviruses that
exhibited significant resistance to MVC under these conditions. Peripheral blood
CD4+ T cells from two uninfected donors, in each of two independent
experiments, were purified by negative selection and stimulated with plate-bound
anti-CD3/anti-CD28 and IL-2 for three days. Cells were incubated in the
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presence or absence of saturating levels of MVC (6µM) 30 min prior to infection.
Three days post-infection, cells were analyzed by flow cytometry and infected
cells were determined by gating on live CD3+CD4-GFP+ events. We found that
the three chronic pseudoviruses exhibited significant residual infection compared
to T/Fs on CD4+ lymphocytes in the presence of saturating MVC (P = 0.04 by ttest) (Fig. 5). Further, these differences reflected those previously observed for
these viruses on high CCR5 Affinofile cells and on NP2/CD4/CCR5 cells (Fig. 5).
The differences were most pronounced on high CCR5 Affinofile cells (which
express the highest levels of CCR5), less pronounced on NP2/CD4/CCR5 cells
(intermediate CCR5 levels), and the least pronounced (but still observable) on
primary CD4+ T cells (low CCR5 levels). Thus, these results are again consistent
with the hypothesis that many CC Envs can utilize MVC-bound CCR5, and that
high levels of CCR5 magnify this property, revealing differences in how T/F and
CC Envs engage this coreceptor.
Ability to use MVC-bound CCR5 is not related to overall level of
infectivity or other viral phenotypes. The ability of some HIV-1 strains to
recognize MVC-bound CCR5 has been linked to differences in how the Env
protein engages its chemokine coreceptor (214, 215, 291). As a result, it is
possible that the striking difference in the frequencies with which T/F and chronic
viruses mediate infection in the presence of MVC, albeit inefficiently at
physiologic levels of CCR5 expression, is a surrogate measure for some other
phenotypic property. In two previous studies, we tested these clade B and C
pseudoviruses in a variety of phenotypic assays, comparing T/F to CC Envs
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(200, 295). With the exception of some clade-specific neutralization sensitivity,
no significant genotypic or phenotypic differences were identified. In light of our
current findings, we re-analyzed these data, comparing Envs that were partially
resistant to MVC on high CCR5 Affinofile cells to 18 previously determined Env
properties (Table 1). None of the phenotypic characteristics previously measured
for these panels correlated strongly with incomplete inhibition by MVC, including
CD4 use efficiency, neutralization by monoclonal antibodies (b12, VRC01, PG9,
PG16) or by pooled sera from patients infected with either clade B or C HIV-1
strains (clade B/C HIV Ig), or primary CD4+ T cell subset tropism. Except for V5
length, we found no strong genetic correlates of incomplete MVC inhibition,
including V1-V4 individual and total variable loop lengths and potential N-linked
glycosylation sites. We also asked whether the ability to utilize CCR5 in the
presence of MVC was simply a property of highly functional Env proteins or
highly infectious Env pseudoviruses. To address this, we plotted pseudoviral
infectivity (RLU) in the absence of MVC against residual infection at saturating
concentrations of MVC. There was no correlation between overall infectivity and
the partial resistance phenotype (Spearman correlation coefficient = 0.02 P =
0.84) (Fig. 6). Therefore, residual infection was not a surrogate measure for
increased infectivity.
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DISCUSSION
In addition to using CCR5 and being T-cell tropic, several other phenotypic
and genotypic traits have been associated with T/F Env proteins relative to those
from chronic viruses (56, 73, 131, 200, 234, 235, 238, 239, 295). Among these,
the differential utilization of CCR5 first observed by Swanstrom and colleagues,
confirmed and extended here, is arguably the most robust. Both clade B and C
T/F Envs are far more likely to be inhibited in entry by MVC on cells expressing
high levels of CCR5 than are CC Envs. The ability of many CC Envs to mediate
infection in the presence of MVC under conditions where CCR5 expression
levels are high indicates that these Envs can utilize one or more conformations of
CCR5 better than most T/F Envs. This suggests that there is selective pressure
against the more promiscuous CCR5 utilization phenotype exhibited by many CC
Envs at the level of HIV transmission and selection for this trait during chronic
infection. Questions that remain to be addressed are the mechanism that
underlie this phenotype, whether genetic signatures associated with differential
use of CCR5 can be identified, and whether this phenotype observed on a cell
line expressing levels of CCR5 that greatly exceed those seen on primary cells is
a correlate for another property that would be more meaningful at the level of
mucosal transmission of HIV-1.
MVC is a CCR5 antagonist that potently inhibits infection by virtually all R5
strains of HIV-1 in vitro (80), blocks vaginal transmission of SHIV-162P3 in a
rhesus macaque model (281), and significantly diminishes virus loads in HIV-1
infected individuals (86). Clearly, MVC is an effective inhibitor of HIV infection
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under most experimental and clinical conditions. Thus, the finding by Swanstrom
and colleagues that approximately one-half of CC Envs are inhibited less than
95% by MVC on 293T cells expressing high levels of CD4 and CCR5 was
surprising. Here, we confirmed this finding using a large panel of Clade C Envs,
and found that Clade B Envs also exhibited this property to a similar magnitude.
What is the mechanism that underlies the differential effects of MVC on
T/F versus chronic HIV-1 Envs? CCR5 antagonists are allosteric inhibitors –
upon binding to CCR5, they induce a conformation that is not recognized by most
HIV-1 strains (26, 82, 130, 133, 250, 276, 288). Thus, the ability of many chronic
HIV-1 Envs to mediate some degree of infection in the presence of saturating
concentrations of MVC could mean that under these conditions a fraction of
CCR5 molecules assume a conformation that is unable to bind MVC but that can
be utilized by many chronic Env proteins.

If so, then CCR5 may exhibit

enhanced conformational heterogeneity when expression levels are high relative
to when expression levels are lower, with one or more of these conformations not
binding MVC or doing so only poorly. CCR5 and seven-transmembrane domain
receptors in general can assume different conformations as a result of binding
ligands or G proteins (18, 50, 84, 186, 187), and CCR5 has been shown to
exhibit antigenic heterogeneity (11, 21, 22, 153). It is also possible that at high
levels of CCR5 expression posttranslational modifications such as sulfation of the
N-terminal domain or coupling to G proteins could become saturated, resulting in
conformational heterogeneity. Thus, our results could be explained by a model in
which one such conformation fails to bind MVC or does so only poorly, with this
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conformation being recognized by a large subset of CC Envs but by only a small
fraction of T/F Env proteins. When coupled with the fact that HIV-1 Env
interactions with CCR5 are variable as judged by the differential effects that
some mutations in CCR5 have on infection by diverse HIV-1 strains (146, 272), it
is certainly plausible that CCR5 conformation could be influenced by expression
levels in a manner that preferentially allows infection by chronic but not T/F
viruses in the presence of MVC.
A second possible mechanism to account for the ability of some Envs to
mediate infection in the presence of MVC when CCR5 levels are high is that
these Envs can utilize the drug-bound conformation of CCR5 very inefficiently,
such that under physiological levels of CCR5 expression infection appears fully
suppressed by MVC and by other CCR5 antagonists. Our data as well as work
by Gorry and colleagues (225) clearly favors this interpretation. Typically, virus
inhibition curves are plotted on a linear scale. However, if inhibition is plotted on
a log-scale and a highly reproducible and quantitative assay is used, different
antiretroviral agents can be revealed to exhibit considerable variability in their
abilities to maximally inhibit HIV-1 (243, 252). When we examined the ability of
MVC to inhibit HIV-1 infection on NP2/CD4/CCR5 cells in this way, it became
apparent that while some viruses were inhibited by 99.9%, others were inhibited
by 99.0% or somewhat less. We found that these small, residual levels of
infection were highly predictive of the ability of a virus to mediate appreciable
levels of infection when both CCR5 and MVC levels are high. When a subset of
viruses were tested on primary human CD4+ T cells in this way, the same results
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were obtained: viruses that mediated obvious levels of infection on CCR5-high
cells in the presence of MVC were inhibited less efficiently than viruses that
remained highly sensitive to MVC regardless of CCR5 expression levels. Roche
et al. have also found that some Envs that appear fully sensitive to MVC on cells
expressing low to moderate levels of CCR5 exhibit some degree of resistance
when CCR5 levels are high (225). Thus, we conclude that using a cell line that
expresses high levels of CCR5 simply amplifies a phenotype that is already
present on cells expressing lower levels of CCR5 that can be easily over-looked
(200, 295).
Given that some R5 HIV-1 strains can mediate readily detectable levels of
infection in the presence of high levels of both CCR5 and MVC, can this
information be used to predict clinical outcomes when MVC is used as part of an
antiviral regimen? The most common mechanism that underlies clinical failure
associated with MVC treatment is expansion of pre-existing viral variants that
utilize CXCR4 to mediate infection (102, 104, 147, 149, 178, 276). Less
commonly, mutations in the Env protein enable it to use MVC-bound CCR5,
sometimes with impressive efficiency (272, 291). The question is whether these
clinical failures are associated with preexisting viruses that are not completely
inhibited by MVC, with this property being clearly evident only when using cells
that express high CCR5 levels. In fact, Roche et al. found that a viral Env
predisposed to acquire high-level resistance to CCR5 antagonists exhibited a low
level ability to use MVC-bound CCR5 on cell lines expressing high levels of this
coreceptor (225). Whether this will be a general property of viral Envs from
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patients who fail MVC via this pathway is not known, but could be examined by
testing the ability of Envs from such individuals to infect Affinofile CCR5-high
cells in the presence of MVC.
The most important question resulting from this work is why the ability to
use MVC-bound CCR5 is associated so clearly with chronic but not T/F Envs.
What results in the selection of this phenotype during the course of natural HIV-1
infection in the absence of MVC therapy, and what selects against this
phenotype at the level of mucosal transmission? Clearly, the reason cannot have
anything to do with MVC per se as none of the patients from whom we derived
Envs had been treated with MVC. Thus, the striking difference between chronic
and T/F Envs seen by Swanstrom and colleagues and in our study is likely a
surrogate for some other viral property. In our previous studies, we compared the
phenotypic properties of panels of T/F and geographically-matched CC Envs
(200, 295). We reanalyzed these data, comparing Envs that were almost totally
inhibited by MVC on CCR5-high cells to those that were not regardless of
whether they were chronic or T/F Envs (Table 1). These analyses failed to
identify any cross-clade phenotypic differences between these two groups,
including the ability to infect different CD4+ T cell subsets, use alternative
coreceptors, neutralization sensitivity, dependence upon CD4 levels, and the
ability to be captured by DCs and transmitted to T cells. In addition, there were
no obvious genetic signatures between the two groups save for a correlation with
V5 loop length, with longer V5 loops being correlated with reduced MPI on high
CCR5 Affinofile cells. While Swanstrom and colleagues found that slightly higher
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glycosylation was associated with the MVC-resistant phenotype (127), this
correlation was not evident in our panel of combined clade B and C Envs. Given
the plasticity with which Envs can interact with their coreceptors and the multiple
Env determinants that can influence CCR5 interactions (137, 142, 143, 146, 170,
260, 263, 265, 272), this is perhaps not surprising: much larger numbers of Env
clones and sequences may be needed to identify genetic characteristics that are
consistently linked with the ability to utilize MVC-bound CCR5. The more
promiscuous utilization of CCR5 conformations by CC Envs may reflect selection
pressures in chronic infection where neutralizing antibodies are abundant and
certain populations of CD4+CCR5+ cells have been diminished or otherwise
altered by viral cytopathicity. Earlier studies have shown that R5 viruses can
become increasingly resistant to entry inhibitors over time, consistent with
alterations in CCR5 use (100, 129, 221). More promiscuous utilization of CCR5
could expand viral tropism under these conditions, in contrast to de novo
infection of naïve hosts where virus infection of a more homogeneous population
of CD4+CCR5+ cells could be favored.

Further characterization of the

CD4+CCR5+ cells that are targeted during acute infection may reveal differences
in the abilities of T/F and chronic Env proteins to mediate virus entry as well as
identify new approaches to prevention.
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FIGURES

Figure 1. Partial resistance to saturating amounts of maraviroc on Affinofile
cells expressing high CCR5. (A) Quantitative assessment of cell surface
expression of CCR5 was determined by staining cells with PE-labeled CCR5
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mAb 2D7 followed by quantitative flow cytometry, making it possible to calculate
the number of 2D7 binding sites per cell. (B) MVC saturation was confirmed by
measuring residual infection between the two highest concentrations used. No
differences in virus inhibition were observed between 2µM and 6µM MVC (P =
0.70). (C) MVC sensitive pseudoviruses dispayed a MPI >95% on both low (grey)
and high (black) CCR5 293-Affinofile cells. Two phenotypes were observed. 57
pseudoviruses and the JRFL control virus displayed a MPI >95% regardless of
CCR5 expression levels (1st and 3rd panels). However, 30 pseudoviruses were
efficiently inhibited by MVC on cells expressing low CCR5, but exhibited MPI
values of ≤95% on high CCR5 Affinofile (middle panel). All experiments were
done in at least triplicate in each of at least three independent experiments. Error
bars represent standard deviations.
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Figure 2. Partial resistance is enriched in chronic HIV-1 Envs compared to
T/F Envs, irrespective of clade and CCR5 antagonist. (A) 87 pseudoviruses
were tested on high CCR5 Affinofile cells. There was a higher frequency of
partial reisistance to MVC in CC Envs compared to T/F Envs (P < 0.0001). (B)
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Data was segregated by clade (52 clade B and 35 clade C) and independently
confirmed an enrichment of the partially resistant phenotype in CC Envs (Clade B
P = 0.02; clade C P = 0.02). (C) Representative resistant (704010330.G5h) and
sensitive (700010040.C9.4520) pseudoviruses were tested for sensitivity to other
CCR5 antagonists on high CCR5 Affinofile cells. Cells were pretreated with
varying concentrations of MVC, aplaviroc, CMPD-167, TAK779, and VVC prior to
infection. MPI values of MVC-resistant (grey) and sensitive (black) pseudovirus
are shown. Data were analyzed by Fisher’s exact test. All infections were done in
at least triplicate in each of at least three independent experiments. Error bars
represent standard deviations.
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Figure 3. Residual infection on cells expressing different levels of CCR5.
All pseudoviruses were tested on low CCR5 Affinofile cells, NP2/CD4/CCR5
cells, and high CCR5 Affinofile cells and the residual infection in the presence of
saturating MVC was plotted for all cell types evaluated. There was a significant
difference between T/F (black) and chronic (grey) residual infection in both
NP2/CD4/CCR5 and high CCR5 Affinofile cells (NP2/CD4/CCR5 P = 0.01, high
CCR5 Affinofiles P = 0.0003), but not on low CCR5 Affinofile cells (P = 0.94).
Data were analyzed by Mann-Whitney test. All experiments were done in at least
triplicate in each of at least two independent experiments.
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Figure 4. Residual infection on cells expressing low levels of CCR5 is
predictive of MVC resistance on cells expressing high CCR5. (A) The
residual infection on low CCR5 Affinofile cells was plotted against that on high
CCR5 Affinofiles in the presence of saturating MVC. Residual infection on low
CCR5 Affinofiles was predictive of partial MVC resistance on high CCR5
Affinofile cells (Spearman correlation coefficient = 0.22; P = 0.04). (B) The
residual infection on high CCR5 Affinofile cells was also plotted against that on
NP2/CD4/CCR5 in the presence of saturating MVC. Similarly, residual infection
on NP2/CD4/CCR5 was predictive of residual infection on high CCR5 Affinofile
cells (Spearman correlation coefficient = 0.65; P < 0.0001).
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10

Figure 5. CC Envs exhibit greater residual infection compared to T/F Envs
on primary human CD4 + T cells. Levels of residual infection for three T/F
(black) and three chronic (grey) Envs on CD4 + T cells were assessed in the
presence of saturating MVC. Higher levels of residual infection were mediated by
CC Envs in the presence of MVC compared to T/F Envs (chronic median = 1.1%
versus T/F median = 0.51%; P = 0.10) . Residual infection for the three T/F and
CC Envs were compared between CD4 + T cells, High CCR5 Affinofile cells, and
NP2/CD4/CCR5 cells . In all three cell types, CC Envs displayed higher residual
infection compared to T/F Envs. All primary cell infections were done with at least
two donors in triplicate in at least two independent experiments.
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Figure 6. Infectivity is not associated with partial resistance phenotype.
Pseudoviral infectivity in the absence of MVC was plotted against residual
infection in the presence of saturating MVC to determine whether partial
reistance correlated with infectivity. There was no correlation (Spearman
correlation coefficient = 0.02; P = 0.84).
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TABLE 1 Genotypic and phenotypic correlates of partial resistance.
!
Env
Type
T/F

Clade

Env clone
designation

Coreceptor
tropism

Geographic
location

Risk
factora Gender

Viral load
(copies/ml)

Fiebig stage/ min time
since infection
Reference

Accession
number

B

REJO.D12.1972

R5

Alabama

HSX

M

722,349

V

2

EU576707

B

THRO.F4.2026

R5

Alabama

MSM

M

5,413,140

V

2

EU577077

B

1018-10.A5.1732

R5

South Carolina

SPD

M

270,000

III

2

EU575091
EU577388

B

WITO.B10.2062

R5

Alabama

HSX

M

325,064

II

2

B

RHPA.A19.2000

R5

Alabama

HSX

F

1,458,354

V

2

EU576734

B

SUMAd5.82.1713

R5

Alabama

MSM

M

939,260

II

2

EU577061

B

700010040.C9.4520

R5

North Carolina

MSM

M

298,026

V

2

EU576418
EU576440

B

700010058.A4.4375

R5

North Carolina

unknown

M

394,649

III

2

B

1053-07.B15.1648

R5

South Carolina

SPD

M

1,400,000

III

2

EU575201

B

9010-09.A1.4924

R5

South Carolina

SPD

F

146,954

II

2

EU575771
EU575795
EU577329

B

9015-07.A1.4729

R5

South Carolina

SPD

M

500,000

II

2

B

TT35P.11H8.2874

R5

Trinidad

HSX

M

1,849,301

II

2

B

9021-14.B2-4571

R5

California

SPD

M

143,379

II

2

EU575924

B

1006-11.C3.1601

R5

North Carolina

SPD

M

1,600,000

III

2

EU575025

B

1056-10.TA11.1826

R5

South Carolina

SPD

M

140,000

II

2

EU575305

B

SC05.8C11.2344

R5

Trinidad

HSX

M

9,980,952

II

2

EU576774

B

SC20.8A8.2437

R5

Trinidad

HSX

M

2,789,313

IV

2

EU576838
EU576114
EU576603

B

9032-08.A1.4685

R5

Alabama

SPD

M

40,815

III

2

B

PRB956-04.B22.4267

R5

Virginia

SPD

n/a

600,000

II

2

B

PRB959-02.A7.4345

R5

South Carolina

SPD

n/a

>2,000,000

II

2

EU576693

B

034v1 (IDU)

R5

Montreal

IDU

M

75,000,000

III

9

GU562170

B

034v2 (IDU)

R5

Montreal

IDU

M

75,000,000

III

9

GU562198

B

AD17.1 env

R5

New York

MSM

M

47,600,000

II

10

n/a

C

706010018. 2E3

R5

S. Africa

HSX

F

93,700

VI

11

FJ444047

C

20258279-V2_3A5

R5

S. Africa

SPD

F

281,838

IV

31

HQ595763
HQ595757

C

2833264_3G11

R5

S. Africa

SPD

M

234,423

I/II

31

C

21197826-V1_3A1

R5

S. Africa

SPD

F

343,923

I/II

31

HQ595753

C

21283649_3E8

R5

S. Africa

SPD

M

3,180

I/II

31

HQ595756

C

20927783_3E2

R5

S. Africa

SPD

F

1,886

I/II

31

HQ595750

234,068

I/II

31

HQ595742

281,838

IV

31

HQ595764

C

1245045_3C7

R5

S. Africa

SPD

C

20258279-V4_3D10

R5

S. Africa

SPD

M
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Env
Type
T/F

Chronic

Clade

Env clone
designation

Coreceptor
tropism

Geographic
location

Risk
factora Gender

Viral load Fiebig stage/ min time
(copies/ml)
since infection
Reference

Accession
number

C

ZM247Fv1.Rev-

R5

Zambia

HSX

F

10,823,500

II

12, 13, 18

n/a

C

ZM249M-B10

R5

Zambia

HSX

M

2,000,000

IV

12, 13, 18

EU166862

C

704809221.1B3

R5

S. Africa

HSX

M

750,000

I/II

11

FJ444116

C

703010054.2A2

R5

Malawi

HSX

M

13,936

V

11

FJ443808

C

703010217.B6

R5

Malawi

HSX

F

102,602

V/VI

11

FJ443589

C

ZM247Fv2.fs

R5

Zambia

HSX

F

10,823,500

II

12, 13, 18

n/a

C

704010042. 2E5

R5

S. Africa

HSX

M

181,000

IV

11

FJ443745

C

705010185.tf

R5

S. Africa

HSX

F

14,800

I/II

in prepb

n/a

B

HEMA.A4.2125

R5

Alabama

MSM

M

49,755

1yr 10mo

2

EU578133

B

SHKE.A7.2118

R5

Alabama

MSM

M

544,000

1yr 2mo

2

EU578458

B

HEMA.A23.2143

R5

Alabama

MSM

M

49,755

1yr 10mo

2

EU578132

B

SHKE.A26.4112

R5

Alabama

MSM

M

544,000

1yr 2mo

2

EU578453

B

WICU.B4.2973

R5

Alabama

MSM

M

8,424

5yr 11mo

2

EU578642

B

OLLA.A14.1923

R5

Alabama

HSX

F

382,000

2yr 1mo

2

EU578231
EU578272

B

SAMI.A8.1863

R5

Alabama

MSM

M

116,000

3yr 11mo

2

B

SHKE.A4.2116

R5

Alabama

MSM

M

544,000

1yr 2mo

2

EU578456

B

SMRE.A13.4127

R5

Alabama

HSX

F

135,858

1yr 4mo

2

EU578471

B

TALA.A2.1780

R5

Alabama

MSM

M

228,200

6yr 11mo

2

EU578494

B

WICU.C1.2992

R5

Alabama

MSM

M

8,424

5yr 11mo

2

EU578657

B

YOMI.F2.4137

R5

Alabama

MSM

M

14,178

6yr 1mo

2

EU578683

B

SC05.A10.2362

R5

Trinidad

HSX

M

19,514

5yr 5mo

2

EU578358

B

SC05.8H2.3243

R5

Trinidad

HSX

M

19,514

5yr 5mo

2

EU576786

B

SC05.8A11.2363

R5

Trinidad

HSX

M

19,514

5yr 5mo

2

EU578359

B

1632-ta9

R5

Washington

MSM

M

97,800

2yr 5mo

26

HQ216892

B

1632-a17

R5

Washington

MSM

M

97,800

2yr 5mo

26

HQ216864
HQ216883

B

1632-a6

R5

Washington

MSM

M

97,800

2yr 5mo

26

B

1632-ta1

R5

Washington

MSM

M

97,800

2yr 5mo

26

HQ216887

B

1632-a7

R5

Washington

MSM

M

97,800

2yr 5mo

26

HQ216884

B

1632-a23

R5

Washington

MSM

M

97,800

2yr 5mo

26

HQ216869

B

1588-ta7

R5

Washington

MSM/ IDU

M

99,600

7yr 2mo

26

HQ216783

B

1470-d27

R5

Washington

MSM/ IDU

M

492,200

4yr 3mo

26

HQ216683

B

1451-d17

R5

Washington

MSM

M

532,000

20yr 3mo

26

HQ216655

B

1451-c16

R5

Washington

MSM

M

532,000

20yr 3mo

26

HQ216638

B

1451-d1

R5

Washington

MSM

M

532,000

20yr 3mo

26

HQ216651
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Env clone
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b
c
d

Geographic
location

Risk
factora Gender

Viral load Fiebig stage/ min time
(copies/ml)
since infection
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Accession
number

B

1599-b11

R5

Washington

IDU

M,F

112,000

6yr 7mo

26

HQ216802

B

1444-a21

R5

Washington

MSM

M

86,300

7yr

26

HQ216583

C

704010330.G5h

R5

S. Africa

HSX

M

46,100

n/a

31

JQ777128

C

704010207.D11

R5

S. Africa

HSX

F

15,400

n/a

31

JQ777073

n/a

31

JQ779320
JQ779232
JQ779889

C

a

Coreceptor
tropism

702010141.E80

R5

Malawi

HSX

F

151,282

C

702010432.E16

R5

Malawi

HSX

M

40,570

n/a

31

C

703010167.E15

R5

Malawi

HSX

F

73,505

n/a

31

C

ZM414.1

R5

Zambia

HSX

F

213,600

n/a

68

GU329415

C

707010457

R5

Tanzania

HSX

F

234,671

n/a

31

KC156220 c

C

ZM414.20

R5

Zambia

HSX

F

213,600

n/a

68

GU329426

C

705010534.E35

R5

S. Africa

HSX

F

63,300

n/a

31

JQ779192

C

704010499.H1

R5

S. Africa

HSX

F

15,200

n/a

31

JQ777164

C

704010461.A7h

R5

S. Africa

HSX

F

22,900

n/a

31

JQ777137

C

704010028.F6

R5

S. Africa

HSX

F

9,220

n/a

31

JQ777039

C

703010269.E30

R5

Malawi

HSX

F

30,434

n/a

31

JQ777184

31

JQ777098

C

704010273. E5

R5

S. Africa

HSX

F

25,700

n/a

C

3902.bmLG14

R5

Malawi

HSX

F

19,900

n/a

C

4403.A18

R5

Malawi

HSX

F

100,892

n/a

C

4403.D1

R5

Malawi

HSX

F

100,892

n/a

C

4403.bmR.B6

R5

Malawi

HSX

F

100,892

n/a

Kirchher JL et
al.c
Kirchher JL et
al.c
Kirchher JL et
al.c
Kirchher JL et
al.c

HM070661
HM070677
HM070689
HM070754

HSX= heterosexual exposure; MSM=men who have sex with men; IDU=intravenous-drug user.
Kappes JC et al. manuscript in preparation.
IMC Accession number.
Kirchherr JL et al.2011. Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology 409:163–174.
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CHAPTER 3
Chemokines and HIV-1: Viral inhibition and enhancement
CHEMOKINES: THE BASICS
Chemokines are a group of low-molecular weight (7 to 12 kDa) secreted
proteins that primarily function in leukocyte development, maturation, and homing
(192). They are also central players in many physiopathological processes such
as allergies, angiogenesis, inflammation, infectious and autoimmune diseases,
tumor growth and hematopoiesis. Chemokines induce chemotaxis in a variety of
cells (monocytes, neutrophils, lymphocytes, eosinophils, fibroblasts, and
keratinocytes) by interacting with chemokine receptors, which are members of
the seven-transmembrane GPCR superfamily and glycosaminoglycans (GAGs)
to promote migration and impart directionality to cell movement (237). GPCRs
couple chemokine binding outside the cell to activation of intracellular signaling
cascades that lead to cell motility. GAGs are complex carbohydrates attached to
protein cores on the cell surface (proteoglycans) or free flowing in the
extracellular space. In addition to numerous functions, GAGs immobilize
chemokines to provide a chemotactic gradient to direct migrating cells to sites of
injury or inflammation (213). To date, more than 50 chemokines and 20
chemokines receptors have been described (Fig 1) (34, 165, 191, 302). Multiple
chemokines can bind and signal through the same receptor, providing
redundancy in chemokine/receptor function.
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As a group, chemokines exhibit between 20-70% amino acid homology
(115, 191) and are characterized by the presence of three to four conserved
cysteine residues. They can be divided into four subfamilies (CXC, CC, C, or
CX3C), based on the positioning of the amino terminal cysteine residues (17).
Structurally, CC-chemokines are defined by the tandem arrangement of cysteine
residues in the amino terminus, while CXC-subfamily cysteines are separated by
a single amino acid. The majority of described chemokines belong to these two
subfamilies. The third subfamily (C) members contain a single cysteine residue in
the conserved position. The fourth subfamily (CX3C) has two cysteines
separated by three variable amino acids in the amino terminus. This subtle
structural difference informs the quaternary structure of the chemokine and has
implications not only for receptor recognition, but also oligomer formation (123,
237). It is well known that chemokines oligomerize in a variety of homo- and
hetero-oligomeric forms at high concentrations both in solution and in
physiological settings to carry out their effector functions (16, 184, 185, 284).
However, studies have reported differences in the quaternary structures of CCand CXC-chemokines and suggested that these differences may be important for
how chemokine subfamilies are recognized by, and signal through, their cognate
receptors and GAGs (123, 195, 216, 220, 286). Therefore the dynamic
equilibrium of chemokine oligomeric states is critical for function, allowing specific
interactions with both GPCRs and GAGs.

60

CHEMOKINES AND HIV-1 PATHOGENESIS
Important discoveries in the last two decades have defined a close
relationship among chemokines, their receptors, and HIV-1 infection (6, 55, 59,
60, 71, 79, 81, 88). For several years, it was known that CD8+ T cells secrete
soluble factors that suppress HIV-1 replication in CD4+ T cells (38, 283).
Supporting evidence for the presence of a noncytolytic suppressive product of
CD8+ T cells came from clinical reports that correlated disease progression with
the absence or presence of CD8+ T cell activity (99, 167). Furthermore, it was
shown that a high level of CD8+ T cell suppressor activity was associated with
long-term survivors of HIV-1 infection (45). Lastly, the noncytolytic activity of
CD8+ T cells controlled disease pathology in nonhuman primates (49, 83, 211).
The identity of these soluble factors remained elusive until Cocchi et
al. demonstrated that the β-chemokines MIP-1α (macrophage inflammatory
protein 1α), MIP-1β (macrophage inflammatory protein 1β) and RANTES
(regulated on activation, normal T expressed and secreted) were responsible for
a significant fraction of the noncytolytic CD8+ T cell suppressive effect (59).
These chemokines, in addition to others belonging to the α-chemokine family (ie:
stromal cell-derived factor 1—SDF-1), suppress viral replication of R5- and X4tropic HIV-1 strains in vitro most commonly by competing with Env for binding to
the cognate chemokine receptor (29, 193). Receptor downregulation in response
to chemokine binding can also suppress viral replication by decreasing the
density of surface coreceptors (8, 166, 254). In vivo studies to corroborate these
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in vitro findings are limited by the inherent difficulties in measuring circulating
chemokine concentrations. However, further research by Cocchi et al.
demonstrated an inverse relationship between levels of β-chemokines in vivo and
the outcome of HIV-1 infection, where higher concentrations of MIP-1α, MIP-1β,
and RANTES from CD8+ T cells correlated with asymptomatic HIV-1 infection
(61). Additionally, nonhuman primate studies have shown that immunization with
simian immunodeficiency virus (SIV) grown in human CD4+ T cells induces
unusually high production of RANTES, MIP-1α, and MIP-1β, which protects
macaques from subsequent SIV challenge (287).
Paradoxically, chemokines have also been described to enhance HIV-1
infection, at least in vitro. RANTES can modulate virus infection in a variety of
ways that are dependent upon its concentration. At low concentrations, RANTES
inhibits HIV-1 infection by blocking its interaction with the viral coreceptor CCR5
(59, 274). At high and likely supra-physiological concentrations, RANTES forms
oligomers that bind to the viral Env protein as well as cell surface GAGs,
enhancing virus attachment and infection (132, 135, 274). RANTES can also
modulate HIV-1 infection by transducing signals via CCR5 that over time render
cells more permissive for viral replication (97, 274). In addition to RANTES,
previous work has demonstrated that the α-chemokine SDF-1 enhances R5tropic, but not X4-tropic, HIV-1 and vesicular stomatitis virus (VSV) infection in
vitro (169). Specifically, SDF-1 was reported to enhance infection via signalingmediated increase of Tat transactivation of the HIV-1 long terminal repeat.
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Additional studies have highlighted novel ways in which chemokines
enhance HIV-1 infection both in vitro and in vivo. In 2007, Saleh et al. identified a
novel mechanism of HIV-1 latent infection of resting CD4+ T cells, in which the
CCR7 ligands, CCL19 and CCL21, were found to significantly increase the
permissiveness of resting CD4+ T cells to HIV-1 infection (241). Interestingly,
this enhancement was attributed to chemokine-mediated increases in viral DNA
nuclear import and integration, but not to productive HIV-1 replication. The same
group further showed that the mechanism of the CCL19-CCR7 interaction is
similar to that of the HIV-1 gp120-CXCR4 interaction in triggering cofilin
activation and actin dynamics, which drastically enhance viral nuclear import and
integration (44, 302). These results are consistent with in vivo data showing that
enhanced levels of CCL19 and CCL21 in HIV-1-infected patients correlate with
viral load, disease progression and response to HAART (70).
Canonically,

chemokine

suppression

of

HIV-1

infection

involves

competitive inhibition of viral entry by binding to the cognate chemokine
coreceptors. These more recent results suggest that HIV-1 infection could also
be affected by chemokines interacting with multiple receptors such as CCR7
(and others not discussed in this section) that may synergize with or antagonize
HIV-1-mediated coreceptor signaling pathways. This widens therapeutic
opportunities and our understanding of viral pathogenesis, as multiple surface
receptors and intracellular signaling molecules might now serve as attractive
targets for therapy.
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PLATELET FACTOR 4 (PF4) AND HIV-1 INFECTION
Although MIP-1α, MIP-1β, and RANTES were initially shown to contribute
to the HIV-1 suppressive effect of CD8

+

T cells, other cells types have been

implicated in the production of anti-HIV-1 chemokines. Several studies have
shown that monocytes, macrophages, and natural killer cells are important
sources of CC- and CXC-chemokines that antagonize HIV-1 entry and replication
in vitro (38, 42, 59, 259, 283). More recently, activated platelets have been
shown to possess anti-HIV-1 properties (259). Platelets are specialized blood
cells that primarily function to promote coagulation at sites of vascular injury by
adhering to subendothelial matrix proteins. During vascular injury, activated
platelets release a number of mediators from their α-granules, including
connective tissue-activating peptide III (CTAP-III/CXCL7), RANTES, and platelet
factor 4 (PF4/CXCL4) (36, 118).
PF4 is a cationic α-chemokine that functions primarily to promote
coagulation by moderating the effects of heparin-like molecules (20, 257), and
can be found in nanomolar and micromolar concentrations within plasma and
serum, respectively (37, 54, 89, 128). PF4 has been shown to be chemotactic for
immune cells by acting through interactions with a splice variant of the GPCR
CXCR3B and an integral chondroitin sulfate proteoglycan expressed on the
surface of cells (140, 150, 181). Additionally, there is evidence that PF4 is
involved in the differentiation of monocytes to macrophages. Recently, PF4 has
been described to possess potent and broadly-active antiviral activity against
HIV-1 in vitro (15, 259).
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The antiviral role of PF4 during HIV-1 infection is not unanticipated, as
several previous studies have linked platelet malfunction and HIV-1 infection—
with thrombocytopenia (platelet count below 150,000cells/mm3) and thrombosis
(clotting) being frequent complications during infection (66, 201, 251). These
hemostatic disorders affect roughly 10-50% of HIV-1-infected individuals (67,
236). Individuals with platelet dysfunctions that increase the risk of thrombosis
are likely to receive heparin treatment (87). PF4 binds with high affinity (4-30nM)
to heparin and heparin-like molecules (163, 264), leading to the development of
ultra large complexes (ULCs), which are highly immunogenic (217). Antibodies
against these ULCs bind to PF4 on platelets and monocytes, activating these
cells, resulting in both thrombocytopenia and thrombosis in a condition known as
heparin-induced thrombocytopenia and thrombosis (HITT) (9). Unsurprisingly,
when the incidence of HITT in HIV-1-infected patients treated with unfractionated
heparin (UFH) therapy was compared with that in an UFH-treated uninfected
control group, HIV-1 infection correlated with increased incidence of HITT (270).
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PROJECT GOAL II: ELUCIDATING THE MECHANISM AND PHYSIOLOGICAL
RELEVANCE OF PF4 ACTIVITY DURING HIV-1 INFECTION

PF4 has been shown to directly inhibit HIV-1 infection in vitro at
concentrations less than 0.5µM (15, 259). However, despite plasma and local
tissue concentrations of PF4 ranging from 0.25nM to 10µM (37, 54, 89, 128),
HIV-1 is able to successfully replicate and escape the inhibitory effects of PF4 in
vivo. The mechanism of this discordance remains unclear. In this study, we
sought to understand the mechanism of action of PF4 and whether it’s in vitro
activity was biologically meaningful in the context of human infection; in an effort
to clarify whether PF4 is a suitable therapeutic candidate for HIV-1 infection.
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CX3C chemokines
C chemokines

CC chemokines

CXC chemokines

Chemokine
CXCL8 (IL-8)
CXCL6 (GCP-2)
CXCL5 (ENA-78)
CXCL1 (GROα)
CXCL2 (GROβ)
CXCL3 (GROγ)
CXCL4 (PF4)
CXCL9 (Mig)
CXCL10 (IP-10)
CXCL11 (I-TAC)
CXCL12 (SDF-1)
CXCL13 (BCA-1)
CXCL16 (SRPSOX)
CXCL7 (NAP-2)
CXCL14 (BRAK)
CXCL15 (Lungkine)
CXCL17 (DMC)
CCL3 (MIP-1α)
CCL4 (MIP-1β)
CCL6(C10)
CCL2(MCP-1)
CCL7 (MCP-3)
CCL8 (MCP-2)
CCL9/CCL10(MRP-2)
CCL14 (HCC-1)
CCL15 (HCC-2)
CCL16 (HCC-4)
CCL23 (MPIF-1)
CCL24 (Eotaxin-2)
CCL26 (Eotaxin-3)
CCL17 (TARC)
CCL22 (MDC)
CCL5 (RANTES)
CCL11 (Eotaxin)
CCL13 (MCP-4)
CCL20 (MIP-3α)
CCL19 (ELC)
CCL21 (SLC)
CCL1 (I-309)
CCL25 (TECK)
CCL27 (CTACK)
CCL28 (MEC)
CCL12 (MCP-5)
CCL18 (PARC)

Receptor
CXCR1

CXCR2
CXCR3B
CXCR3
CXCR4
CXCR5
CXCR6
CXCR7
Unknown

CCR1
CCR2
CCR2B
CCR5
CCR1
CCR2
CCR3
CCR4
CCR5
CCR6
CCR7
CCR8
CCR9
CCR10
Unknown

XCL1 (Lymphotactin α)
XCL2 (Lymphotactin β)

XCR1

CX3CL1 (Fractalkine)

CX3CR1
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Figure 1: Known human
chemokines and chemokine
receptors. More than 50
chemokines and 20 chemokine
receptors have been identified to
date. The difference in numbers,
coupled with the fact that multiple
chemokines can bind to, and signal
through, the same chemokine
receptor suggests a redundancy in
chemokine/receptor function.
(Image adapted from Wu et al
Retrovirology 2010; 7:86)
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ABSTRACT
Platelet-factor 4 (PF4) has been recently shown to inhibit infection by a
broad range of HIV-1 isolates in vitro. We found that the inhibitory effects of PF4
are limited to a defined concentration range where PF4 exists largely in a
monomeric state. Under these conditions, PF4 bound the HIV-1 envelope protein
and inhibited HIV-1 attachment to the cell surface. However, as concentrations
increased to the point where PF4 exists largely in tetrameric or higher-order
forms, viral infection in vitro was enhanced. Enhancement could be inhibited by
mutations in PF4 that shift the oligomeric equilibrium towards the monomeric
state, or by using soluble glycosaminoglycans (GAGs) to which tetrameric PF4
avidly binds. We conclude that at physiologically relevant concentrations,
oligomeric PF4 enhances infection by HIV-1 by interacting with the viral envelope
protein as well as cell surface GAGs, enhancing virus attachment to the cell
surface. This effect was not specific to HIV-1, as enhancement was seen with
some but not all other viruses tested. The biphasic effects of PF4 on HIV-1
infection suggest that native PF4 will not be a useful antiviral agent, and that PF4
could contribute to the hematologic abnormalities commonly seen in HIV-infected
individuals by enhancing virus infection in the bone marrow.
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) entry into target cells
results from sequential interactions between the HIV-1 envelope glycoprotein
(Env) with the cellular receptor CD4 and a coreceptor, either CCR5 or CXCR4 (6,
55, 71, 79, 81, 88). The efficiency of this process can be regulated in vivo by
cytokines and chemokines that bind to the viral coreceptors or that influence
coreceptor expression levels (38, 42, 59, 74). A variety of cell types secrete
cytokines or chemokines that can modulate HIV infection, including activated
platelets that have been shown to possess anti HIV-1 properties in vitro (38, 42,
59, 259, 283).
During vascular injury, activated platelets release a number of mediators
from their α-granules, including connective tissue-activating peptide III (CTAPIII/CXCL7), RANTES (CCL5), and Platelet-factor 4 (PF4/CXCL4) (36, 118). PF4
is a cationic α-chemokine that functions primarily to promote coagulation by
moderating the effects of heparin-like molecules (20, 257). PF4 is present in
nanomolar and micromolar concentrations within plasma (0.5 to 3 nM) and serum
(0.4 to 1.9 µM), respectively (37, 54, 89, 128). PF4 has been shown to be
chemotactic for immune cells by acting through interactions with a splice variant
of the G-protein coupled receptor CXCR3B and cell surface proteoglycans (140,
150, 181). Recently, PF4 has been described to possess potent and broadlyactive antiviral activity against HIV-1 in vitro at concentrations less than 0.5 µM
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(15, 259), though the mechanism and in vivo relevance of these results are
uncertain.
In this study, we find that the previously reported inhibitory effects of PF4
are limited to a narrow concentration range where PF4 exists predominantly as a
monomer (172). Under these conditions, PF4 binds directly to Env and inhibits
virus infection by preventing its attachment to the cell surface. At physiologic
concentrations, where PF4 exists largely as a tetramer, it enhanced infection
several-fold above untreated controls. This biphasic activity of PF4 was not
restricted to the HIV-1 Env, as we observed similar results with HIV-1
pseudoviruses bearing the glycoproteins of murine leukemia virus (HIV-1MLV),
simian immunodeficiency viruses (HIV-1SIVmac316 and HIV-1SIVsmmE660) and
vesicular stomatitis virus (HIV-1VSV-G). However, PF4 did not antagonize nor
enhance the entry of pseudoviruses bearing the glycoprotein of influenza (HIV1H5N1). We further demonstrated that PF4 carries out its dual activity during viral
infection by modulating viral attachment to the cell. Lastly, we provide evidence
that oligomeric PF4 directly interacts with cellular glycosaminoglycans (GAGs) as
well as the HIV-1 envelope glycoprotein gp120, perhaps serving as a bridge
between cell surface GAGs and the viral envelope glycoprotein, thus enhancing
virus attachment and infection at high PF4 concentrations. This could play a role
in vivo, as PF4 produced in the bone marrow could impact virus infection of stem
cells and other progenitors, contributing to the hematologic abnormalities
commonly associated with HIV/AIDS.
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METHODS
Cell Culture. 293T17 and HeLa-derived JC53 cells were maintained in
Dulbecco’s modified Eagle medium (DMEM) with 10% (vol/vol) fetal bovine
serum (FBS)—D10F media. Multinuclear activation of galactosidase indicator
cells stably expressing human CD4 and CCR5 (MAGI-CCR5) were obtained from
the National Institutes of Health-AIDS Research and Reference Reagent
Program and maintained in DMEM supplemented with 10% FBS and 1mg/ml
puromycin. SupT1-CCR5 and Jurkat-CCR5 immortalized cell lines were
maintained in Roswell Park Memorial Institute (RPMI) medium containing 10%
FBS (R10F media). Primary human CD4+ T cells were obtained from the Human
Immunology Core of the University of Pennsylvania’s Center for AIDS Research.
Virus production and normalization. HIV-1 Env pseudoviruses were
produced by calcium phosphate co-transfection of 6 µg of pcDNA3.1+ containing
the desired env clone with 10 µg of HIV-1 core (pNL43-∆Env-vpr+ -luc+ or pNL43∆Env-vpr+ -eGFP) into 293T17 cells. At 72 hr post-transfection, the pseudoviruscontaining supernatant was harvested and filtered through a 0.45-µm-pore-size
filter and stored at -80°C. Influenza (H5N1) pseudoviruses were produced by
calcium phosphate co-transfection of 400 ng of pCMV8/R containing H5 (VRC
7705) and 100 ng of pCMV8/R containing N1 (VRC 7708) with 10 µg of HIV-1
core (pNL43-∆Env-vpr+ -luc+) into 293T17 cells. HEPES buffer (1:100; Invitrogen)
was added to the media to maintain basic pH and minimize acid-induced HA
triggering. At 48 hr post-transfection, the pseudovirus-containing supernatant
was harvested as described for HIV-1 Env pseudoviruses. GFP pseudoviruses
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were concentrated approximately 100-fold by ultracentrifugation at 113,000 x g
for 2 hr at 4°C through a 20% sucrose cushion. Pelleted pseudovirus was then
resuspended in phosphate-buffered saline (PBS) and stored at -80°C.
Virus inhibition assay. MAGI-CCR5 cells were treated with varying
concentrations of PF4 or media only prior to infection with the indicated luciferase
reporter pseudovirus or full-length infectious molecular clone. After addition of
pseudovirus, plates were spinoculated at 1,200 x g for 2 hr at 4°C and then
incubated at 37°C. Viral inoculum was replaced with fresh complete media
(supplemented with PF4 for replication competent infections) after 4 hr. Inhibition
assays were also conducted with the SupT1-CCR5 and Jurkat-CCR5 cell lines
as described above. For single-cycle infections using luciferase-encoding
pseudovirus, cells were lysed with Brite-Glo (Promega) at 72 hr postinfection,
and relative light units (RLUs) were measured. For spreading infections of
replication competent infectious virus, HIV-1 replication was assessed by
measuring p24 Gag protein in cell-free culture supernatants taken between days
3 and 9 postinfection using a commercial enzyme immunoassay (AlphaLISA;
Perkin-Elmer). All inhibition assays were done in at least duplicate in each of at
least three independent experiments.
Viral attachment assay. Human CD4+ T cells (106 cells per condition)
were stimulated for 3-5 days with anti-CD3/anti-CD28 beads (Invitrogen) and 20
U/ml recombinant interleukin-2 (IL-2; Aldesleukin; Prometheus Laboratories) in
R10F media. Cells were pretreated with 200 μl of 200 nM or 4 μM PF4WT with or
without 10 μg/ml soluble heparan sulfate proteoglycan (HSP), 4 μM PF4K50E, 15
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μM maraviroc (MVC), 15 μM plerixafor (AMD3100), 40 μg/ml DEAE-dextran, or
serum-free PBS at room temperature for 30 mins. Cells were subsequently
exposed to 200 μl of undiluted HIV-1R3A (2.3 µg p24/ml) and incubated at 37°C
for 4 hr in the absence or presence of each drug treatment. To determine
background signal level, 2 x 106 untreated cells were infected and incubated at
4°C for 4 hr. After incubation, cells were washed twice in PBS to remove
unbound virus. Cells were then split into two aliquots: one aliquot was treated
with 50 μl of prewarmed 0.05% trypsin-EDTA at 37°C for 10 mins, followed by
trypsin inactivation with 5 ml cold R10F media. The other aliquot was left trypsinuntreated in R10F media. Both trypsin-treated and -untreated cells were washed
three times with cold PBS, then the cell pellets lysed with 100 μl of 0.5% (wt/vol)
Triton X-100. Cell-associated p24 was measured using the p24 AlphaLISA
(Perkin-Elmer). The final p24 concentration was calculated by subtracting the
concentration of the trypsin-treated cells incubated at 4°C from the p24 signal
measured in each test sample.
Primary human CD4+ T cell infections. Primary human CD4+ T cells
(106 cells per condition) were stimulated with anti-CD3/anti-CD28 magnetic
beads (Invitrogen) and 20 U/ml recombinant IL-2 in R10F media. Three days
post-stimulation, cells were transferred to 24-well plates and incubated for 30 min
with no PF4, 200 nM PF4, or 4 µM PF4. Viral input was normalized by reverse
transcriptase (RT) activity as determined by a colorimetric assay (Roche).
Approximately 3 ng RT of replication competent HIV-1CH077 was used to infect
cells in duplicate in a total volume of 250 µl. Plates were incubated at 37°C, and
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media was replaced every 48 hr with fresh IL-2 containing R10F with PF4. HIV-1
replication was assessed by measuring the p24 Gag protein in cell-free culture
supernatants collected 6 days postinfection. Assays were done in duplicate with
each of at least three independent donors.
Generation and purification of PF4 in S2 cells. cDNA encoding human
PF4 was cloned into the plasmid pMT/BiP/V5-His A (Invitrogen) for expression.
PF4 expression was induced by adding copper sulfate (0.5mM) to S2 cells. The
induced S2 cells were then incubated in serum-free medium Insect-Xpress
(Lonza) for 3 to 5 days; supernatants were collected and the media filtered
through a 0.22-µm filter. PF4WT was purified from the media on a heparin HiTrap
column on an ATKA Prime (GE Healthcare) at 4°C in 10 mM Tris, 1 mM EDTA,
pH 8.0 buffer. Media were loaded in buffer containing 0.5 M NaCl, and PF4 was
eluted at 1.8 M NaCl using a linear gradient. Fractions containing purified PF4 as
detected by silver staining of 12% NuPAGE Bis-Tris gels (Invitrogen) were
pooled, concentrated, and the buffer was exchanged into 50 mM HEPES, 0.5 M
NaCl, pH ~7.2 using an Amicon Ultra centrifugal filter (3K NMWL; Millipore).
Protein was quantified using a bicinchoninic acid assay (Pierce Chemical).
PF4K50E and PF4E28R/K50E were purified as PF4WT, with the following
modifications: the column buffer system used was 50 mM MES, 1 mM EDTA,
and pH 6.5. Media were loaded in buffer containing 0.3 M NaCl and the proteins
were eluted at 1.3 M NaCl using a linear gradient. Commercially available PF4
isolated from human platelets (Calbiochem) and commercially available
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recombinant PF4 (R&D Systems) were tested along with laboratory-generated
recombinant PF4.
Enzyme-linked immunosorbent assay (ELISA). Chemokines were
immobilized on 96-well plates (Immulon 4HBX; Thermo Scientific) in PBS-/- (Life
Technologies) overnight at room temperature. Wells were washed three times
with 250 µl PBS containing 0.1% Tween-20 (PBST), followed by blocking with
200 µl of 1% BSA in PBS (BPBS) at room temperature for 1 hr. Wells were then
washed three times with PBST. In binding experiments, 50 µl of purified gp120
was added to chemokine-coated or control wells and allowed to react for 30 mins
at room temperature. Wells were then washed three times. To detect bound
gp120, 50 µl of a gp120-specific polyclonal rabbit serum (1170) created in our
laboratory (1:1250 dilution in BPBS) was added to wells and reacted at room
temperature for 30 mins. The wells were washed three times before the addition
of 50 µl HRP-conjugated secondary goat anti-rabbit antibody (1:2500 dilution in
BPBS; Cell Signaling Technology). After 30 mins reaction at room temperature,
the wells were washed six times. To visualize color, 100 µl of the
tetramethylbenzidine (TMB) substrate solution (R&D Systems) was added to the
wells. The OD450 was measured using an MRX Revelation microplate reader
(Dynex Technologies) immediately after the addition of 50 µl 2 N sulfuric acid
stop solution (R&D Systems).
Antibody inhibition assays. PF4 was preincubated in the absence or
presence of 2X excess RTO or KKO anti-hPF4 antibodies at room temperature
for 25 mins. The antibody-PF4 mixture was then added to MAGI-CCR5 cells prior
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to infection with the indicated luciferase reporter pseudovirus. After addition of
pseudovirus, plates were spinoculated at 1,200 x g for 2 hr at 4°C and then
incubated at 37°C. Infection inoculum was replaced with fresh complete media
after 2 hr. Cells were then lysed with Brite-Glo (Promega) at 72 hr postinfection,
and RLUs were measured.
Statistical analysis. Infection values obtained with or without PF4
treatment were compared using t tests. P values of less than 0.05 were
considered significant. Data were analyzed with Prism 5.0 software.
Ethics statement. These studies were approved by the University of
Pennsylvania’s Institutional Review Board. All human cells used in this study
were from normal healthy donors who provided written informed consent.
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RESULTS
PF4 exhibits a biphasic effect on HIV-1 entry. Initial studies evaluating
the effect of recombinant human PF4 on HIV-1 infection in vitro demonstrated
that PF4 possesses broad antiviral activity against multiple HIV-1 genetic clades,
irrespective of coreceptor tropism (15, 259). We utilized an independent panel of
previously described (200, 295)14 clade B and 9 clade C HIV-1 Envs (Table 1) to
further explore the antiviral properties of this chemokine. Of the 23 Envs tested,
18 were CCR5 (R5)-tropic, one was CXCR4 (X4)-tropic, and four were R5/X4
(dual)-tropic, and 12 of the 23 Envs were derived from transmitted/founder (T/F)
viruses (96, 121, 131, 136, 200, 238, 239). Multinuclear activation of
galactosidase indicator cells stably expressing human CD4 and CCR5 (MAGI-R5
cells) (53) were pretreated with increasing concentrations of recombinant PF4 for
30 minutes, and subsequently infected with HIV-1 Env pseudoviruses. PF4
inhibited infection by all HIV-1 Env pseudoviruses tested, with maximal inhibition
occurring at approximately 200 nM added protein (mean % inhibition = 85 ± 6; p
< 0.0001). T/F Envs were inhibited as efficiently as Envs derived from other
viruses. However, when PF4 was added at concentrations above 200 nM,
infection was inhibited less efficiently and was enhanced above (mean %
infection = 174 ± 67; p < 0.0001) that of untreated controls at the highest
concentration of PF4 tested (Figs 1A and 1B).
For our studies, we tested commercially available PF4 isolated from
human platelets, commercially available recombinant PF4, as well as laboratoryproduced recombinant PF4. We found that both recombinant forms of PF4
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impacted HIV-1 infection identically over a broad concentration range, while the
concentration needed for native PF4 to maximally inhibit (24 nM) and then
enhance (200 nM) HIV-1 infection was approximately one-log less, perhaps
reflecting inefficient refolding of the recombinant proteins. Nonetheless, as all
three forms of PF4 exhibited similar biphasic effects on HIV-1 infection, we
proceeded with the laboratory-developed recombinant PF4 for subsequent
experiments.
The MAGI assay was also performed utilizing replication competent R5-,
X4-, and dual-tropic HIV-1 (CH141, HxB, and R3A, respectively). As was
observed with the pseudoviruses, 200 nM PF4 maximally inhibited infection of
the clade C primary isolate HIV-1CH141 (mean % inhibition = 93 ± 4; P = 0.0007),
the clade B primary isolate HIV-1R3A (mean % inhibition = 86, ± 10; P = 0.0044),
and the laboratory-adapted strain HIV-1HxB (mean % inhibition = 90 ± 9; P =
0.0034). In contrast, at 4 µM, PF4 enhanced infection of all three viruses by 2-3
fold (Fig 1C). A saturating concentration of the membrane fusion inhibitor
enfuvirtide (T20) was used as a negative control in these experiments, inhibiting
infection of all three viruses by 94-99% of untreated control.
PF4 activity is evident on multiple cell types against a variety of
viruses. To evaluate whether the activity of PF4 was specific to the MAGI-R5
cells, CD4+ T cell lines stably expressing CCR5 (SupT1-R5 and Jurkat-R5) and
primary human CD4+ T cells were infected with either HIV-1 pseudoviruses or
replication competent HIV-1 in the absence or presence of PF4. The biphasic
activity of PF4 was observed in all cell types with all viruses tested (Fig 1D).
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These results confirm the findings of previous studies (15, 259), that infection by
R5- and X4-tropic HIV-1 strains is reduced in the presence of PF4. However, the
inhibitory effects of PF4 were limited to a relatively narrow concentration range,
above which viral infection in vitro was consistently enhanced.
To assess the specificity of anti-viral PF4 activity, we examined the ability
of HIV-1 pseudotyped viruses bearing the envelope glycoproteins from
SIVsmE660, SIVmac316, MLV, influenza (H5N1) or VSV to infect MAGI-R5 cells in
the absence or presence of increasing concentrations of PF4. Infection by HIV1SIVmac316 and HIV-1MLV was robustly inhibited by PF4 at approximately 200 nM
(mean % inhibition = 84 ± 1; p value < 0.0001 and 95 ± 2; P = 0.0002,
respectively), but significantly enhanced (mean % infection = 265 ± 71; p <
0.0212 and 286 ± 65; P = 0.0015, respectively) by 4 µM PF4. Infection by HIV1VSV-G and HIV-1SIVsmmE660 was inhibited to a lesser degree (mean % inhibition =
78 ± 5; P = 0.0013 and 70 ± 20; P = 0.0256, respectively) with inhibition being
lost as PF4 concentrations were increased, while HIV-1H5N1 infection was
unaffected by PF4 (mean % inhibition = 4 ± 8; P = 0.2483) (Fig 1E). Given that
these pseudoviruses share a common HIV-1 core (NL4.3) yet were inhibited to
varying degrees by PF4, we conclude that both the inhibitory as well as the viral
enhancement effects of PF4 occur at the level of entry and are not restricted to
HIV-1.
PF4 modulates viral entry by acting on viral attachment. To explore
the mechanism of action by which PF4 modulates HIV-1 infection, we first
performed time of addition experiments and found that, as previously reported
80

(15), PF4 most strongly inhibited HIV-1 when added before or simultaneously
with the virus, consistent with it impacting HIV-1 entry (data not shown). To
determine if PF4 impacts the first step of virus infection – binding of virions to the
cell surface – we examined the ability of low and high concentrations of the
chemokine to interfere with viral attachment. For this purpose, primary human
CD4+ T cells were exposed to HIV-1R3A for 4 hr at 37°C in the presence or
absence of PF4. Cells were then split into two aliquots; one aliquot was treated
with trypsin to remove attached viral particles remaining on the cell surface, while
the other aliquot was left untreated. Attachment was measured by quantifying
total vs. trypsin-resistant cell-associated HIV-1 p24 Gag protein. When added at
200 nM, PF4 inhibited virus infection and also significantly reduced viral
attachment to cells by 55% ± 9% compared to the no treatment control (P =
0.0008) (Fig 2). In contrast, the infection-enhancing concentration of PF4 (4 µM)
increased viral attachment to primary cells by 61% ± 12% relative to the no
treatment control (P = 0.0006). The polycation DEAE-dextran was used as a
positive control and enhanced viral attachment 42-fold above the untreated
control (P = 0.0004). The coreceptor small molecule antagonists maraviroc
(MVC) and AMD-3100, which block viral engagement of CCR5 and CXCR4
respectively, had no significant effect on viral attachment as expected (Fig 2).
These data suggest that low levels of PF4 inhibit viral infection by decreasing
viral adsorption to cells, while higher concentrations of the chemokine enhance
viral attachment and thus increase infection.
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PF4 interacts with cellular GAGs. PF4 could potentially impact virus
attachment by interacting with cell surface components, with the viral
glycoprotein or with both. There is considerable evidence that many chemokines
interact with cell surface GAGs which in turn facilitate attachment of many
viruses to cells (106, 125, 213). To determine if PF4 may interact with cell
surface molecules in a manner that impacts virus attachment, we treated MAGIR5 cells with an inhibitory concentration of PF4 (200 nM) for 30 minutes, then
either washed the cells with PBS (wash) or left unwashed (no wash), and
subsequently infected with HIV-1 pseudovirus. We hypothesized that if PF4’s
mechanism of action entailed interactions with the viral glycoprotein, then prebinding to the cell surface followed by washing should have little impact on virus
infection. If, however, PF4 binds to a cell surface molecule that participates in
virus attachment, then washing off pre-bound PF4 should reduce the
chemokine’s effect on virus infection depending on the affinity of the interaction.
Pre-binding PF4 to the cell surface followed by extensive washing decreased
subsequent infection by HIV-1MLV, HIV-1JRFL, and HIV-1VSV-G by 45% ± 12% (P =
0.016), 51% ± 7% (P = 0.007), and 24% ± 16% (P = 0.13), respectively (Fig 3A);
consistent with PF4 interacting with a cell surface molecule(s) to antagonize viral
infection. As expected, pre-binding and then washing PF4 from cells had no
effect on HIV-1H5N1 infection (mean % infection = 106 ± 9; P = 0.4080) (Fig 3A).
Since it is well established that PF4 binds to negatively charged GAGs
such as heparan sulfate proteoglycans (HSP) and chondroitin sulfate
proteoglycans (CSP),(141, 163, 205, 231) we performed competition assays
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using soluble HSP. MAGI-R5 cells were infected with HIV-1 pseudoviruses in the
presence or absence of increasing concentrations of soluble HSP and no, low
(200 nM), or high (2 µM) concentrations of PF4. As the concentration of soluble
HSP was increased, the ability of the low concentration of PF4 to inhibit infection
waned, eventually reaching the same level as no PF4. In addition, high amounts
of HSP ablated the capacity of the high concentration of PF4 to enhance
infection (HIV-1JRFL shown in Fig 3B). Similar results were observed with soluble
CSP (data not shown). The fact that soluble HSP reduced the ability of PF4 to
inhibit virus infection and entirely ablated the ability of high concentrations of PF4
to enhance virus infection could be linked to virus binding—at inhibitory
concentrations of PF4, the presence of 10 µg/ml soluble HSP slightly increased
virus binding (mean % cell-associated p24 200nM vs. 200nM + HSP = 55 ± 9 vs.
70 ± 9; P = 0.3), while at enhancing concentrations of PF4 the presence of HSP
strongly reduced virus binding to the cell surface (mean % cell-associated p24 =
57 ± 7; P < 0.0001) (Fig 3C). These data are consistent with PF4 being able to
bind to GAGs, particularly at high PF4 concentrations, with this in turn being
linked to enhanced virus binding to the cell surface.
HIV-1 gp120 binds specifically to PF4. The ability of PF4 to bind to
GAGs does not, by itself, explain how it can enhance virus infection at high
concentrations. Therefore, we hypothesized that at high concentrations, PF4
might function as an electrostatic bridge between virions and cell surface GAGs
to modulate attachment. If this is true, not only should PF4 interact with cell
surface GAGs, it should also interact with the virus. To test this, we assessed the
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ability of purified HIV-1 envelope glycoprotein gp120 to bind to polystyreneimmobilized PF4 by ELISA. Graded amounts of PF4 were immobilized overnight
before incubation with varying concentrations of purified HIV-1JRFL gp120 for 30
mins. After washing, bound gp120 was detected using a rabbit polyclonal serum
(4). We found that gp120 bound to PF4 in a concentration-dependent manner
(Fig 4A). Likewise, gp120 also bound to RANTES in a concentration-dependent
manner, consistent with previous work (274). In contrast, gp120 failed to bind to
immobilized IL-8 or SDF-1 using the same assay conditions (Fig 4B). From
these results, we conclude that the bimolecular interaction observed between
gp120 and PF4/RANTES is direct and has some degree of specificity.
PF4 oligomerization state correlates with its effects on virus
infection. PF4 in solution exists in a dynamic state; at low concentrations it is
largely monomeric, while at high concentrations it forms tetramers (20, 172, 179,
233). Chemical cross-linking was used to confirm this equilibrium using the
recombinant PF4 used in our studies (217). Although this equilibrium exists in
solution in vitro, under physiologic conditions it has been hypothesized that PF4
exists primarily as a tetramer and avidly binds to heparin and GAGs to form the
ultra-large antigenic complexes noted in the clinical disorder of heparin-induced
thrombocytopenia (HIT) (10, 20, 116, 172, 179, 217). Mutations that decrease
the formation of PF4 tetramers have been shown to reduce the formation of
these large complexes. Rauova et al. disrupted the ionic interactions between
recombinant PF4 dimers by substituting Lys at position 50 with Glu to create
PF4K50E, which shifts the equilibrium of PF4 to favor dimers and monomers (217).
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Additionally, a double mutant was generated in which the Glu28 and Lys50 in PF4
were replaced with Arg and Glu (PF4E28R/K50E) to reinstate the ionic interactions
between dimers, significantly restoring the ability to form tetramers at high
concentrations (217). Given this concentration-dependent oligomerization of PF4
and its two opposing effects on viral entry, we reasoned that inhibition might be
linked to the presence of monomers that bind directly to Env and prevent it from
interacting with the cell surface, whereas PF4 tetramers may function to enhance
viral infection by forming a bridge between cell surface GAGs and Env, overriding
the inhibitory effect and thereby enhancing virus attachment.
To explore the effect of oligomeric state on PF4 activity, MAGI-R5 cells
were infected with HIV-1 pseudoviruses in the absence or presence of increasing
concentrations of recombinant PF4WT, PF4K50E, or PF4E28R/K50E. For all viruses
tested, PF4K50E exhibited an approximately 1-log increase in IC50 compared to
PF4WT, while the double mutant PF4E28R/K50E partially rescued this loss in potency
(Fig 5A). As previously observed, HIV-1JRFL and HIV-1MLV infection was
enhanced approximately 2-fold of untreated control (mean % infection = 210 ± 51
and 200 ± 32, respectively) at the highest concentration (4 µM) of PF4WT tested.
Relative to PF4WT, 4 µM of the monomer-favoring PF4K50E did not enhance, but
rather inhibited HIV-1JRFL and HIV-1MLV infection (mean % inhibition = 66 ± 11; P
= 0.028 and 63% ± 8%; P = 0.008, respectively), while the complementary
mutant PF4E28R/K50E restored the enhancing activity (mean % infection = 121 ± 9;
p =0.45 and 136% ± 18%; P = 0.16, respectively), although not to the levels of
PF4WT (Fig 5A & 5B). Compared to the untreated control, HIV-1VSV-G infection was
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inhibited by 4 µM PF4K50E (mean % inhibition = 33 ± 9; P = 0.0154), but not
significantly impacted by 4 µM PF4WT or PF4E28R/K50E (mean % infection = 97 ±
16; P = 0.89 and 104 ± 11; p =0.19, respectively) (Fig 5A & 5B). Additionally, we
tested the ability of PF4K50E to modulate viral attachment as we had previously
done with low and high concentrations of PF4WT. As observed with the low
concentration of PF4WT, the monomer-favoring PF4K50E significantly decreased
viral attachment at 4 µM compared to untreated controls (% cell-associated p24
= 35 ± 6; p < 0.0001) (Fig 5C). From these data, we conclude that the antiviral
property of PF4 occurs under conditions where tetramers are not prevalent, while
the presence of tetramers is associated with enhancement of viral infection.
Antibodies that recognize distinct oligomeric forms of PF4 were used to
further probe the role of oligomeric state on PF4 activity during viral infection.
The monoclonal anti-hPF4 antibody RTO selectively binds to PF4 monomers
while the HIT-like monoclonal antibody KKO induces the oligomerization of PF4
tetramers and preferentially recognizes large complexes comprised of PF4
tetramers (13, 232). If monomers and dimers are responsible for the inhibitory
effect of PF4 on virus infection, then both RTO and KKO should ablate the
inhibitory effect of 200 nM PF4, which in fact we observed (Fig 6). However, at 4
µM PF4 where preformed tetramers predominate, the antibodies should differ in
their effects—RTO should not impact PF4 activity since it preferentially binds
monomers, while KKO may further enhance infectivity by inducing even greater
PF4 oligomerization which enhances attachment of virus to the cell surface. We
found this to be the case, with KKO further enhancing infectivity of both HIV-1JRFL
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and HIV-1MLV pseudotypes in the presence of 4 µM PF4 (Fig 6). These results
further support the hypothesis that oligomeric forms of PF4 enhance viral
infection.
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DISCUSSION
Increased platelet activation, thrombocytopenia, and thrombosis are
complications associated with HIV-1 infection (10, 66, 113, 201, 251). Several
studies describe an anti-viral role for chemokines released from activated
platelets including RANTES and PF4 (15, 59, 259). RANTES can modulate virus
infection through diverse mechanisms that are dependent upon its concentration.
At low concentrations, RANTES can inhibit HIV infection by blocking its
interaction with the viral coreceptor CCR5 (12, 40, 59, 166, 193, 256, 274, 275).
At high, and likely supra-physiological concentrations, RANTES forms higherorder oligomers that bind to the viral Env protein as well as cell surface GAGs,
enhancing virus attachment and infection, at least in vitro (274). RANTES can
also modulate virus infection by transducing signals via CCR5 that over time
render cells more permissive for virus replication (97). Likewise, we find that PF4
can both inhibit and enhance HIV-1 infection in a concentration-dependent
manner, with enhancement being observed at PF4 concentrations likely to be
found in proximity to cell surfaces.
Recent studies that examined the impact of PF4 on HIV-1 infection
suggested that the in vitro inhibitory effects of PF4 could be exploited
therapeutically (15, 259). Enhancement of infection by PF4 was not reported in
these studies, though concentrations greater than 650 nM were not tested.
However, a previous study by Schwartzkopff et al. showed that higher
concentrations of PF4 (4 µM) actually enhanced HIV-1 infection in macrophages
(249). The availability of recombinant PF4, PF4 mutations that impact its
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oligomeric properties, and oligomeric-state specific anti-PF4 antibodies allowed
us to more fully explore this chemokine’s biphasic effects on HIV-1 infection. We
confirmed earlier findings that at low concentrations PF4 inhibits HIV-1 infection
by approximately 1-log, and linked this inhibition to the ability of PF4 to bind
directly to the gp120 subunit of the viral Env protein and to decrease binding of
virions to the cell surface. However, PF4 also inhibited infection by several other
viruses that bear little similarity to HIV-1, and inhibited all of the genetically
diverse HIV-1 strains that we tested indicting that it has broad anti-viral potency.
From this we conclude that while PF4 can engage the viral Env protein, it likely
does so in a relatively non-specific manner that may well limit its therapeutic use.
Further, the fact that PF4 inhibited infection of all HIV-1 strains we tested in vitro
suggests that it has not applied sufficient selective pressure in vivo to drive the
development of widespread resistance.
PF4 exists in dynamic equilibrium in solution, where monomers assemble
into tetramers via dimer intermediates in a concentration dependent manner (20,
172, 179, 233). However, it is likely that under physiological conditions PF4
exists predominantly as a tetramer complexed with GAGs (20, 116, 172, 179).
The biphasic effect of PF4 on HIV-1 infection can be explained by its tendency to
oligomerize at physiologically relevant concentrations and its ability to bind to cell
surface GAGs in a manner analogous to RANTES (20, 116). As PF4
concentrations increased, with a concomitant shift toward tetrameric and higherorder complexes, the inhibitory capacity of PF4 waned and viral infection was
ultimately enhanced. This finding was observed for all HIV-1 strains tested as
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well as virions bearing the SIV and MLV glycoproteins. Collectively, these data
suggest that in vivo, where PF4 likely exists primarily as a GAG-associated
tetramer, the inhibitory effects of the monomeric chemokine are less likely to
predominate.
The mechanism by which PF4 enhanced virus infection at high
concentrations was again at the level of virus binding. Like most chemokines,
oligomeric PF4 binds with high affinity to polyanionic GAGs such as heparin and
heparan sulfate proteoglycans (HSP) (264). Since PF4 can also bind to the viral
Env protein, we hypothesized that PF4 oligomers can function as an electrostatic
bridge between virions and cell surface GAGs. In support of this hypothesis, we
found that high concentrations of PF4 enhanced virus binding, and that the
addition of soluble heparan and chondroitin sulfate proteoglycans significantly
mitigated the enhancing, but not the inhibitory, effects of PF4 by decreasing viral
attachment to cells. This is not entirely surprising, as PF4 tetramers have been
shown to exhibit higher affinity for GAGs due to their favorable quaternary
structure, which exposes a ring of basic amino acids (264, 305). Additionally, by
promoting oligomerization, the HIT-like antibody KKO likely induced the formation
of ultra large complexes of PF4 tetramers that further potentiated the basal
enhancement effect of 4µM PF4 in vitro.
While RANTES and PF4 can both inhibit viral infection at low
concentrations, the mechanisms are different: RANTES inhibits virus infection in
a highly specific manner by interacting with the viral coreceptor while PF4 inhibits
HIV-1 infection by binding to the viral Env protein. In contrast, both chemokines
90

can enhance virus infection at high concentrations by forming higher-ordered
complexes and enhancing virus binding to cells through interactions with cell
surface GAGs. However, while the concentrations at which RANTES enhances
HIV-1 infection in vitro are unlikely to be found in vivo, it is likely that
physiological concentrations of PF4 can enhance virus infection. These findings
underscore the importance of examining the full spectrum of relevant
concentrations when assessing the impact of chemokines on virus infection given
their ability to form oligomers that in turn influence their interactions with cell
surface molecules. In addition, it is possible that the enhancing effect of PF4 on
virus infection could impact HIV-1 pathogenesis. PF4 is produced by
megakaryocytes in the bone marrow leading to intramedullary release (Lambert
M et al., submitted), and regulates hematopoietic stem cell cycle activity (39).
The presence of PF4 in the bone marrow could enhance HIV-1 infection of stem
cells and other progenitors, contributing to the well-documented hematopoietic
abnormalities that are common in HIV-infected individuals.
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Figure 1: PF4 exhibits biphasic activity on viral entry. (A) 14 clade B and (B)
9 clade C HIV envelope pseudotypes were tested on MAGI-R5 cells in the
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absence or presence of increasing concentrations of PF4. PF4 inhibited infected
of all Env pseudoviruses tested at concentrations below 200nM. However, at
concentrations above 2μM, infection of all viruses was enhanced 2-5 fold by PF4.
(C) The dual activity of PF4 was recapitulated with CCR5- and CXCR4-using
replication competent HIV-1. (D) PF4 exhibited biphasic activity against a
replication competent dual-tropic primary HIV-1 isolate (CH077) on multiple cell
lines. (E) The effect of PF4 was not specific to HIV-1 envelope as the dual
activity was evident to varying degrees with HIV-1 pseudoviruses bearing the
glycoprotein of SIVmac316, SIVE660, VSV, and MLV. HIV-1 pseudotypes
bearing the influenza glycoprotein H5N1 infection was unaffected by the
presence of PF4. All experiments were done in at least triplicate in each of at
least three independent experiments. Error bars represent standard deviations.
ns p > 0.05, * p < 0.05, ** p < 0.005, *** p < 0.0001
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Figure 2: PF4 modulates viral attachment to cells. Replication competent
HIV-1 R3A binding to the cell surface was assessed in the absence or presence
of PF4. The inhibitory concentration of PF4 (200nM) significantly decreased viral
attachment to cells compared to the untreated control (% cell-associated p24 =
55.2 ± 9.4; p = 0.0008). Contrastingly, the enhancing concentration of PF4 (4μM)
significantly increased viral binding to cells compared to control (% cellassociated p24 = 161.3 ± 12.5; p = 0.0006). The positive control DEAE-dextran
increased viral attachment approximately 42-fold above control (% cellassociated p24 = 4207.0 ± 790.7; p = 0.0004). The small molecule coreceptor
antagonists maraviroc (MVC) and AMD3100 served as negative controls and did
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not impact viral attachment as they work downstream of early attachment events.
All experiments were done in duplicate with three donors in at least three
independent experiments. Error bars represent standard error.
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Figure 3: PF4 interacts withcell surface glycosaminoglycans. (A)
To address whether PF4 interacts with a cell surface molecule to
modulate infection, cells were pretreated with 200nM PF4 and either
washed five times with PBS or left unwashed, followed by infection
with HIV-1 pseudoviruses bearing the glycoprotein of either ML V,
H5N1, JRFL, or VSV. Washing off PF4 before infection reduced entry
by approximately 2-fold. Infection was inhibited at least 3-fold when
PF4 was left on cells. The negative control H5N1 infection was
unaffected by either treatment. (B) Ef fect of cell surface GAGs on PF4
activity. Infection of JRFL was measured in the presence of 0nM,
200nM, or 2000nM PF4 with increasing concentrations of soluble
HSP. 10μg/ml HSP significantly diminished the effect of 2000nM PF4
on viral infection, impacting infection aprroximately 18-fold. HSP had
a 2-fold effect on infection in the presence of low concentrations of
PF4 and in the absence of PF4. (C) Addition of soluble heparan sulfate
proteoglycan (HSP) to the low concentration of PF4 did not signifi cantly impact its effect on viral binding. However, adding HSP to the
high concentration of PF4 significantly decreased cell-associated virus
to levels comparable to 200nM PF4 (% cell-associated p24 = 56.7±
7.5; p < 0.0001). All experiments were done in at least triplicate in each
of at least three independent experiments. Error bars represent standard
deviations. ns p > 0.05, ** p < 0.005, *** p < 0.0008, **** p < 0.0001

Figure 3: PF4 interacts with cell surface glycosaminoglycans.

(A) To

address whether PF4 interacts with a cell surface molecule to modulate infection,
cells were pretreated with 200nM PF4 and either washed five times with PBS or
left unwashed, followed by infection with HIV-1 pseudoviruses bearing the
glycoprotein of either MLV, H5N1, JRFL, or VSV. Washing off PF4 before
infection reduced entry by approximately 2-fold. Infection was inhibited at least 3fold when PF4 was left on cells. The negative control HIV-1H5N1 infection was
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unaffected by either treatment. (B) Effect of cell surface GAGs on PF4 activity.
Infection of HIV-1JRFL was measured in the presence of 0nM, 200nM, or 2000nM
PF4 with increasing concentrations of soluble HSP. 10μg/ml HSP significantly
diminished the effect of 2000nM PF4 on viral infection, impacting infection
aprroximately 18-fold. HSP had a 2-fold effect on infection in the presence of low
concentrations of PF4 and in the absence of PF4. (C) Addition of soluble
heparan sulfate proteoglycan (HSP) to the low concentration of PF4 did not
significantly impact its effect on viral binding. However, adding HSP to the high
concentration of PF4 significantly decreased cell-associated virus to levels
comparable to 200nM PF4. All experiments were done in at least triplicate in
each of at least three independent experiments. Error bars represent standard
deviations.
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Figure 4: HIV-1 gp120 binds specifically to immobilized PF4. (A) Graded
amounts of PF4 were immobilized overnight before incubating with varying
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Figure 5: PF4 oligomeric state correlates with its biphasic activity on viral
infection. (A) MAGI-R5 cells were infected with HIV-1 pseudoviruses bearing the
glycoprotein of MLV (top), JRFL (middle), and VSV (bottom) in the absence or
increasing presence of PF4WT, PF4K50E, or PF4E28R/K50E. (B) Virus entry was
measured at high (4μM) concentrations of PF4WT, PF4K50E, or PF4E28R/K50E.
PF4WT enhanced infection of HIV-1JRFL and HIV-1MLV approximately 2-fold.
PF4K50E significantly inhibited HIV-1JRFL, HIV-1MLV, and HIV-1VSV-G entry.
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PF4E28R/K50E restored the enhancement observed with PF4WT.

PF4WT and

PF4E28R/K50E did not significantly impact HIV-1VSV-G entry. (C) High concentrations
of the monomer-favoring mutant PF4K50E significantly reduced viral binding to
cells. All experiments were done in at least triplicate in each of at least three
independent experiments. Error bars represent standard deviations. ns p > 0.05,
* p < 0.05, ** p < 0.005, *** p < 0.0001
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Figure 6: Antibodies recognizing distinct oligomeric forms of PF4 impact
chemokine activity during infection. 0, 200nM, or 4µM PF4 was preincubated
in the absence or presence of excess RTO or KKO anti-hPF4 antibodies. The
mixture was then added to MAGI-R5 cells, followed by HIV-1JRFL (top) or HIV-1MLV
(bottom) infection. For both pseudoviruses tested, RTO and KKO did not
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significantly impact viral infection in the absence of PF4. However, both
antibodies prevented 200nM PF4-mediated viral inhibition. At 4µM PF4, RTO did
not impact viral enhancement compared to no antibody control. KKO further
enhanced viral infection in the presence of 4µM PF4. All experiments were done
in at least triplicate in each of at least three independent experiments. Error bars
represent standard deviations. ns p > 0.05, * p < 0.05, ** p < 0.005, *** p <
0.0001

103

TABLE I Summary of T/F and chronic HIV-1 env clones

Env
Type

Clade

Numerical
designation

Env clone
designation

Coreceptor
tropism

Reference

Accession
number

T/F

B

1

REJO.D12.1972

R5

27

EU576707

B

2

WEAUd15.410.5017

R5/X4

27

EU289202

B

3

700010058.A4.4375

R5

27

EU576440

B

4

700010077.SA2.6559

R5/X4

27

EU578999.2

B

5

TT35P.11H8.2874

R5

27

EU577329

B

6

1006-11.C3.1601

R5

27

EU575025

B

7

1056-10.TA11.1826

R5

27

EU575305

B

8

1058-11.B11.1550

R5/X4

27

EU289187

C

1

2833264_3G11

R5

32

HQ595757

C

2

1245045_3C7

R5

32

HQ595742

C

3

ZM246F.F

R5

28-30

n/a

C

4

ZM247Fv2.fs

R5

28-30

n/a

B

9

CRPE.B28.4072

R5/X4

27

EU578065.1

B

10

JOTO.TA1.2247

X4

27

EU578181.1

B

11

OLLA.A14.1923

R5

27

EU578231

B

12

SAMI.A8.1863

R5

27

EU578272

B

13

SHKE.A26.4112

R5

27

EU578453

B

14

1632-a6

R5

31

HQ216883

C

5

704010330.G5h

R5

32

JQ777128

C

6

702010141_w12_e80.F

R5

32

JQ779320

C

7

704010461.A7h

R5

32

JQ777137

C

8

4403.A18

R5

33

HM070677

C

9

4403.bmL.B6

R5

33

HM070754

Chronic
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CHAPTER 5
Summary, discussion, and future directions
PROJECT I: T/F AND CC DIFFERENTIALLY UTILIZE CCR5
The concept of selective HIV-1 transmission was initially suggested by
studies assessing envelope (env) diversity between donor-recipient pairs
(transmission pairs) (299, 300, 304, 307). While these studies incited substantial
interest and work in this area, they were limited by the fact that they were
relatively qualitative in nature—chronically infected individuals were described as
harboring genetically diverse viral quasispecies, and acutely-infected individuals
could be grouped as having a “homogenous” or “heterogeneous” infection, born
of a single donor viral variant or multiple closely-related donor variants,
respectively. Thus, while it was apparent that HIV-1 transmission involved a
genetic bottleneck, a more quantitative approach to enumerate and define the
characteristics of transmitted viruses was required. The development of singlegenome amplification (SGA) aimed to precisely identify and quantitatively
characterize the transmitted/founder (T/F) virus(es).

SGA involves limiting

dilution of vRNA/cDNA, such that only a single template is amplified, followed by
amplicon sequencing (131). SGA overcomes the limitations of conventional PCR
followed by cloning and sequencing of the amplified template by eliminating Taq
polymerase-induced recombination and ensuring proportional representation of
target sequences (197, 238, 253, 255). Using this method, George Shaw and
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colleagues were able to unambiguously infer the T/F env lineage of 98 out of 102
acutely-infected individuals; each lineage was characterized by a distinctive set
of identical or near identical sequences (131). Subsequent cloning and in vitro
characterization of pseudoviruses bearing each of these Envs, demonstrated that
all T/F Envs were functional; capable of mediating CD4- and CCR5-dependent
cell entry. This is expected as these Envs successfully initiated infection in a new
host. In contrast, it is not uncommon to find nonfunctional Envs in cloned Envs
from chronically infected individuals (136, 200, 240). Studying SGA-derived T/F
Envs has revealed that the most consistent property associated with transmitted
viruses is the use of the CCR5 coreceptor (24, 51, 121, 131).
CCR5 is a seven-transmembrane domain G-protein-coupled receptor
(GPCR) that primarily functions as a chemokine receptor to regulate trafficking
and the effector response of leukocytes. While CCR5 use is a major contributor
to the genetic bottleneck, it is clear that on average one, or a select few, CCR5using (R5-tropic) variants with specific genetic signatures (see Chapter 1) cross
the mucosal epithelium to infect a new host. The use of CCR5 to mediate viral
entry can be inhibited by the small molecule antagonist maraviroc (MVC). MVC,
and other small molecule antagonists discussed in chapter 1, function as
allosteric inhibitors, inducing a conformational change of CCR5, which prevents
the viral envelope glycoprotein (Env) gp120 from engaging the coreceptor.
However, some viruses become resistant to MVC by acquiring mutations that
enable them to recognize and bind to the drug-bound conformation of CCR5.
Thus, coreceptor conformation is clearly important. We know that, like other
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GPCRs (139), CCR5 exists in different conformations, perhaps related to
membrane

microdomains

(186,

187),

differences

in

posttranslational

modifications such as sulfation and glycosylation (50, 84), and coupling to G
proteins (226, 269). We and others have shown that distinct CCR5 conformations
can been detected on multiple cell types through the use of conformationdependent antibodies (25, 153). Additionally, studies on MVC resistant viruses
have shown variability in how viruses can productively engage CCR5—with
some being more reliant on the amino terminus of CCR5, while others
preferentially engage the second extracellular loop (3, 272). Moreover, some
viruses are naturally resistant to CCR5-antagonists like MVC and can mediate
entry via antagonist-bound CCR5 (108, 271). Given this background, it is logical
to ask whether T/F viruses interact with CCR5 in a manner that is different from
what is seen with viruses isolated from chronically infected individuals (chronic
controls—CC). Understanding this phenotypic difference in coreceptor usage can
provide insight into how Env-CCR5 interactions shape transmission fitness, and
also inform the development of tests to better predict whether a patient will
benefit from a CCR5-antagonist therapy.
While we know that there exists a continuum of CCR5 engagement by
various HIV-1 strains, the implications of these interactions are unknown. We
were interested in understanding how various viruses interact with CCR5—
particularly, different conformations of CCR5, and whether this interaction was
meaningful in the context of transmission. To this end, we evaluated a panel of
87 CCR5-using viruses (from MVC treatment-naïve patients) to address
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differences between T/F and CC viruses in their ability to mediate entry via CCR5
in the presence of MVC. Our lab had previously reported no statistical difference
in MVC sensitivity between subtypes B and C T/F and CC viruses on a microglial
cell line—NP2/CD4/CCR5—stably expressing human CD4 and CCR5 (200, 295).
In project I, however, we described a difference in the magnitude of MVC
inhibition of T/F and CC viruses that was readily apparent on cells with high
surface levels of CCR5. We can modulate cell surface expression of CCR5 using
the 293-derived Affinofile cell line (126). Affinofile cells expressing low or high
levels of CCR5 were infected with each of 87 viruses in the absence or presence
of increasing concentrations (to saturating levels—6µM) of MVC, after which we
calculated the maximal percent inhibition (MPI). The MPI measures residual
entry of resistant viruses in the presence of MVC. We imposed an arbitrary MPI
cutoff of 95%, where MPI values >95% were considered fully sensitive (FS) to
MVC, while samples with MPIs ≤95% were defined as partially resistant (PR) to
MVC. All 87 viruses were inhibited by >95% at 6µM MVC on low-CCR5
Affinofiles. However, on high-CCR5 Affinofiles, only 66% of the viruses were
inhibited by MVC by >95%, while 34% of the viruses exhibited PR in the
presence of 6µM MVC, with some viruses exhibiting extensive MVC resistance.
These results were confirmed using additional CCR5 antagonists, replication
competent HIV-1, and on primary human CD4+ T cells. When we parsed the
viruses in our panel by Env type, we found a difference in the frequency with
which T/F and CC viruses exhibited partial MVC resistance (15% and 52%,
respectively). From these data, we conclude that at baseline, there is a
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significant variability in MVC MPI among different viral isolates and that the
magnitude of this variability is in part dependent on CCR5 expression.
Furthermore, these results suggest that T/F and CC viruses differentially utilize
CCR5 to mediate entry (111).
What does differential utilization of CCR5 signify in the context of
transmission? The fact that the PR phenotype segregates with CC Envs
suggests that this property is favored by the virus during a chronic infection, but
disadvantageous to the virus (and likely selected against) during transmission
and acute infection. One hypothesis is that at later stages of infection, when the
virus is pressured by the host immune system and readily available target cell
numbers precipitously decline, the ability to use multiple conformations of CCR5
could expand the availability of CD4+ CCR5+ target cells. Indeed, Paul Gorry and
colleagues have shown that R5-tropic viruses become increasingly resistant to
CCR5 inhibitors with time, consistent with changes in CCR5 use (100, 221).
Another hypothesis is that different conformational variants of CCR5 exist
on

mucosal

targets

cells

that

are

readily

available

during

acute

infection/transmission, compared to CD4+ CCR5+ cells in the blood or other distal
tissues later in infection. Employing a number of mAbs specific for different
epitopes on CCR5, Berro et al (25) revealed the existence of multiple antigenic
forms of CCR5 expressed on the surfaces of U87/CD4/CCR5 cells and CD4+ T
cells. The authors further showed that CCR5 antagonist-sensitive and -resistant
viruses use the forms of coreceptor differentially for entry in the presence or
absence of CCR5 antagonists. These results and our data suggest that
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differences in CCR5 conformation may provide additional insights into the
coreceptor determinants of the PR phenotype and the significance of this
phenotype during HIV-1 transmission/pathogenesis.
Future studies should aim to define the molecular determinants of the PR
phenotype and address the impact of differential CCR5 usage on mucosal
transmission. First, chimeras can be used to elucidate the viral and coreceptor
contribution to the PR phenotype by identifying Env and coreceptor molecular
determinants of this phenotype. CCR5 is known to be conformationally dynamic,
thus, comparing the conformational forms of CCR5 on target cells from mucosal
tissue to those on blood-derived target cells using monoclonal antibodies will
reveal whether there exists differences in CCR5 antigenic forms in distinct
compartments. Next, it is important to investigate the role of this phenotypic
difference during mucosal transmission in vivo. The bone marrow-liver-thymus
(BLT) humanized mouse model may be a suitable system for these studies
because it has been shown to be the only mouse model that leads to the
generation of a human mucosal immune system. Additionally, the model has
been shown to faithfully repopulate the mouse female reproductive tract with the
appropriate human immune cells (DCs, Macrophages, and T cells) (72).
Moreover, these mice exhibit high numbers of human immune cells in the blood,
as well as organs and tissues (176). Together these experiments will define the
mechanisms and implications of variable CCR5 usage during mucosal
transmission, which may provide new insights into HIV-1 therapy.
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PROJECT II: PF4 INHIBITS AND ENHANCES HIV-1 INFECTION
Recent studies have described an anti-viral role for platelets (259). These
specialized anucleated blood cells release a number of chemokines to promote
coagulation. One such platelet-derived chemokine is platelet factor-4 (PF4),
which was recently described to posses potent and broad anti-HIV-1 activity (15,
259). However, despite in vivo plasma and local concentrations of PF4 being
within the range used in these studies (36), HIV-1 is still able to establish
productive infection. In this study, we sought to understand the mechanism of
action of PF4 and whether it’s in vitro activity was biologically meaningful in the
context of human infection.
Utilizing a distinct panel of primary HIV-1 isolates and other viruses, we
showed that the inhibitory effects of PF4 are not restricted to HIV-1 and
constrained to a narrow concentration window. As the concentration of PF4
increased, the inhibitory capacity of the chemokine waned, and infection was
ultimately enhanced. Although PF4 was broadly active against a number of
different retroviruses, the fact that it exhibited modest effects on VSV-G entry and
no effect on H5N1 infection suggests that the chemokine functions in a relatively
non-specific manner. Using an ELISA assay, we demonstrated that HIV-1 Env
gp120 binds specifically and directly to immobilized PF4. However, exactly where
PF4 binds on the viral envelope glycoprotein remains unclear—Auerbach et al.
suggest that PF4 interacts with HIV-1 gp120 at a site proximal to (but not
including) the CD4 binding site to inhibit infection (15). However, since not all
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PF4-sensitive viruses require CD4 for entry, the precise site of PF4 binding on
the viral envelope glycoprotein may have more generalizable characteristics,
such as net charge or quaternary structure.
Auerbach et al. and Tsegaye et al. demonstrated potent antiviral activity of
recombinant PF4 and activated platelet supernatant, respectively. Neither study
reported the enhancing activity of PF4 we observed, though concentrations
above 650nM were not tested. However, consistent with what we report here,
previous research by Schwartzkopff et al. showed that high amounts of PF4
(4µM) potentiated HIV-1 infection in macrophage-colony stimulating factor (MCSF)-derived macrophages (249). The observation that PF4, at higher
concentrations, enhanced viral infection is not surprising, as the enhancing role
of certain CC-chemokines has been well characterized (97, 135, 183, 274).
Trkola et al. reported that RANTES oligomers increase viral infectivity in vitro
(274). The similarities between how RANTES and PF4 enhance viral infection
are striking in that high concentrations (presumably oligomers) of both
chemokines interact with glycosaminoglycans (GAGs) to increase viral
attachment to the cell surface and subsequent infection. As was reported with
RANTES, we also show specific interaction between HIV-1 gp120 and PF4, but
not with other cationic chemokines (stromal derived factor-1 (SDF-1) and IL-8).
Additionally, the effects of RANTES are also relatively non-specific as infection of
HIV-1 pseudovirus bearing the glycoprotein of MLV or VSV is also enhanced.
There are key differences, however, between the two chemokines that
influences their role in modulating viral infection. First, RANTES and PF4 belong
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to different subfamilies of chemokines; the former belongs to the CC-subfamily
and the latter to the CXC-chemokine subfamily. Structurally, CC-chemokines are
defined by the tandem arrangement of cysteine residues in the amino terminus,
while CXC-subfamily cysteines are separated by a single amino acid. This subtle
structural difference informs the quaternary structure of the chemokine and has
implications not only for receptor recognition, but also oligomer formation (123,
237). It is well known that chemokines oligomerize in a variety of homo- and
hetero-oligomeric forms at high concentrations both in solution and in
physiological settings to carry out their effector functions (16, 184, 185, 284).
However, studies have reported differences in the quaternary structures of CCand CXC-chemokines and suggested that these differences may be important for
how chemokine subfamilies are recognized by, and signal through, their cognate
receptors (123, 195, 216, 220, 286). To illustrate this point, Trkola et al. report
that one mechanism by which RANTES enhances infection is by signaling
through its G protein-coupled receptor CCR5. In addition to RANTES, previous
research has shown that the α-chemokine SDF-1 enhances R5-tropic, but not
X4-tropic, HIV-1 and VSV-G infection (169). Specifically, SDF-1 was reported to
enhance infection via signaling-mediated increase of Tat transactivation of the
HIV-1 long terminal repeat. In our study, however, two lines of evidence suggest
that signaling via the PF4 receptor CXCR3B plays no appreciable role in the
chemokine’s activity during infection; first, time-of-addition experiments showed
that infection was inhibited or enhanced when PF4 was added either before or
simultaneously with virus. It is reasonable to assume that if signaling was critical,
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only with PF4 pretreatment of cells (presumably allowing sufficient binding and
signaling events to occur) would PF4 possess anti- or proviral effects. Second,
pretreating cells with an antibody to PF4’s receptor CXCR3B inhibited agonistinduced phosphorylation of Akt and p44/42 (Erk1/2), but did not ablate the
biphasic activity of PF4 during viral infection (data not shown). It is possible that
longer (>24 hrs) PF4 pretreatment could result in signaling-mediated effects on
viral infection as observed with RANTES and SDF-1.
Another significant difference between RANTES and PF4 that influences
their role in modulating viral infection is the range of in vivo concentrations. The
concentrations at which RANTES enhances infection is supraphysiological and
unlikely to be found in vivo (274). However, PF4 concentrations that enhance
viral infection (> 2µM) in vitro are likely to be present in vivo, where
concentrations at local sites of platelet degranulation can be as high at 10µM
(308). This suggests that, unlike RANTES, PF4 could modulate HIV-1
pathogenesis by enhancing HIV-1 infection in vivo. Therefore, while RANTES,
SDF-1, and PF4 similarly inhibit and enhance viral infection in a relatively nonspecific manner, understanding the differences in how these chemokines
execute the same functions may elucidate a new paradigm for how we think
about chemokines and their role during viral infection, and might reveal new
virus-chemokine interactions that could influence virus infection in vivo.
It is well documented that chemokines require interaction with GAGs in
vivo to carry out their primary effector function of directing the migration of
leukocytes to sites of injury or during usual immune surveillance (125, 144, 213).
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Chemokine binding to GAGs on endothelial cells and extracellular matrix serves
as a gradient to direct cell migration (2, 41, 227). Without this anchoring
interaction, the chemokine would freely disperse, effectively lowering the
concentration needed to activate its cognate receptor (213). This is verified by
the fact that chemokines that are engineered to lack the GAG-binding domain
can still interact with their cognate receptors, but fail to induce cell migration in
vivo (5, 206, 213). Thus, it was logical to assume that GAGs likely play a role in
the activity of PF4 during viral infection. Like most chemokines, PF4 binds with
high affinity to polyanionic GAGs such as heparin and heparan sulfate
proteoglycans (HSP) (156, 257). Moreover, it is secreted from activated platelets
in conjunction with chondroitin sulfate proteoglycans (20, 116, 155). We showed
that a cell surface molecule was partially involved in the activity of PF4 as
evidenced by the fact that washing cells thoroughly post PF4 pretreatment before
infection still decreased viral entry. Furthermore, we found that the addition of
soluble GAGs (heparan and chondroitin sulfate proteoglycans) significantly
mitigated the enhancing, but not the inhibitory, effect of PF4 by decreasing viral
attachment to cells. This is not entirely surprising, as PF4 tetramers have been
shown to exhibit higher affinity for GAGs due to their favorable quaternary
structure, which exposes a ring of basic amino acids (264, 305). Since we
observed the greatest impact of soluble GAGs in the presence of high
concentrations of PF4, one might predict that uncoupling GAG-binding from PF4
would attenuate or ablate the tetramer-related enhancement of infection.
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PF4 exists in dynamic equilibrium in solution, where monomers aggregate
into tetramers via dimer intermediates in a concentration dependent manner (20,
172,

179,

233).

However,

under

physiological

conditions

PF4

exists

predominantly as a tetramer complexed with chondroitin sulfate proteoglycans
(20, 116, 172, 179). Noticing that the biphasic activity of PF4 correlated with its
concentration, we postulated that oligomeric state might contribute to the antiand proviral effects. To address this, we utilized PF4 mutants that differ in their
ability to oligomerize, while still retaining functionality (217). At comparably high
concentrations (4µM), wildtype PF4 enhanced infection by HIV-1 JRFL, the
monomer-favoring PF4K50E decreased infection, and the complementary mutant
PF4E28R/K50E restored the enhancing phenotype. From this, we concluded that
the monomeric state of PF4 correlated with inhibition, while the presence of
tetrameric PF4 (or absence of monomers) was associated with increasing viral
infection. If monomers were fully responsible for the inhibitory effect we
observed, we would predict that the monomer-favoring PF4K50E would be at least
as potent as wildtype PF4 in inhibiting infection. However, we noted that the
K50E mutation reduced the potency of PF4, while the complementary mutant
PF4E28R/K50E partially restored the loss in potency. As mentioned above, PF4K50E
and PF4E28R/K50E are both able to bind heparin comparable to wildtype PF4 (217),
thus this decrease in potency is not due to a defect in chemokine function. We
cannot, however, rule out the possibility that introducing a mutation(s) into PF4
may affect other properties/domains of the protein that are important for its antior proviral activity, while only subtly affecting anionic-binding functionality.
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Increased platelet activation and heparin-induced thrombocytopenia and
thrombosis (HITT) are complications associated with HIV-1 infection (66, 201,
251). PF4 is produced by megakaryocytes in the bone marrow and regulates
hematopoetic stem cell cycle activity. The presence of PF4 in the bone marrow
could enhance HIV-1 infection of stem cells and other progenitors, contributing to
the well-documented hematopoietic abnormalities that are common in HIVinfected individuals. The heightened activation of platelets leads to enhanced
release of platelet-derived chemokines such as RANTES (113) and PF4.
Previous studies examining the role of PF4 in HIV-1 infection have suggested
that the potent in vitro inhibitory effects of PF4 may be exploited in vivo to
prevent transmission. Though an attractive option, it may not be feasible given
the data we describe in project II. In this study, we demonstrate that the inhibitory
capacity of PF4 was confined to a narrow concentration range characterized by
the prevalence of PF4 monomers. As monomers aggregate to form tetramers at
high concentrations, we found that the inhibitory capacity of PF4 waned and viral
infection was ultimately enhanced. Collectively, these data suggest that in vivo,
where PF4 exists primarily as a GAG-associated tetramer, the inhibitory effects
of the chemokine are less likely to predominate. In fact, enhancement of viral
infection is most likely the physiological impact of PF4 during viral infection.
Whereas Auerbach et al. reported that three of 13 primary HIV-1 isolates were
resistant to PF4 inhibition, none of the 23 primary viruses used in this study
showed a resistance phenotype. This suggests that PF4 has perhaps not applied
sufficient pressure in vivo to drive the development of widespread resistance.
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In vivo studies on the role of chemokines in a disease setting are
inherently difficult to perform and can only prove association, not causation.
However, further studies could examine the in vivo dynamics of PF4 and HIV-1
pathogenesis. Specifically, measuring endogenous PF4 production levels (both
locally and systemically) and/or genetic polymorphisms in PF4 and the impact on
HIV-1 infection. Additionally, retrospective studies can be performed on HIV-1
patients with platelet dysfunction to assess whether PF4 (and other platelet
chemokines such as RANTES) levels correlate with disease progression and
pathology. These studies would be informative for whether endogenous PF4
levels (in addition to CD4+ T cell count) could be used as a prognostic factor in
HIV-1 disease.
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